ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -4 مورد

Citalopram: Pediatric drug information

Citalopram: Pediatric drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Citalopram: Drug information" and "Citalopram: Patient drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Suicidal thoughts and behaviors:

Antidepressants increased the risk of suicidal thinking and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. Citalopram is not approved for use in pediatric patients.

Brand Names: US
  • CeleXA
Brand Names: Canada
  • ACT Citalopram [DSC];
  • AG-Citalopram;
  • APO-Citalopram;
  • Auro-Citalopram;
  • BIO-Citalopram [DSC];
  • CCP-Citalopram [DSC];
  • CeleXA;
  • Citalopram-10;
  • Citalopram-20;
  • Citalopram-40;
  • CTP 30;
  • DOM-Citalopram [DSC];
  • M-Citalopram;
  • Mar-Citalopram;
  • MINT-Citalopram;
  • NAT-Citalopram [DSC];
  • NATCO-Citalopram;
  • NRA-Citalopram;
  • PMS-Citalopram;
  • Priva-Citalopram [DSC];
  • RAN-Citalo [DSC];
  • RIVA-Citalopram;
  • SANDOZ Citalopram [DSC];
  • SEPTA-Citalopram [DSC];
  • TEVA-Citalopram
Therapeutic Category
  • Antidepressant, Selective Serotonin Reuptake Inhibitor (SSRI)
Dosing: Pediatric

Dosage guidance:

Safety: Doses >40 mg/day are not recommended due to risk of QTc prolongation.

Dosing: Initiate at a low dose and with a slow titration to reduce the potential for behavioral activation/agitation that may occur with therapy initiation particularly in younger children (Ref).

Anxiety disorders

Anxiety disorders (generalized, social, or separation anxiety, or panic disorder): Limited data available:

Note: In pediatric patients, selective serotonin reuptake inhibitor (SSRI) therapy is considered first-line pharmacologic treatment for moderate to severe anxiety disorders in combination with cognitive behavioral therapy (CBT); a preferred SSRI has not been defined; therapeutic selection should be based on pharmacokinetic and pharmacodynamic data, patient tolerability, cost, and unique risks/precautions with specific agents (eg, QT prolongation) (Ref).

Children ≥7 years to <12 years: Oral: Initial range: 2.5 to 10 mg once daily; titrate to target daily dose range: 10 to 20 mg/day. In trials, an initial dose of 10 mg/day titrated slowly every 1 to 2 weeks was reported; however, subsequent expert recommendations suggest in younger patients that lower initial doses (<10 mg) and slow titration be used to prevent dose-related behavioral activation/agitation that may occur early in treatment; some data based on trials treating OCD (a type of anxiety disorder) (Ref).

Children ≥12 years and Adolescents: Initial: 10 mg once daily; titrate at 1- to 2-week intervals up to a target daily dose of 20 to 40 mg/day (Ref).

Depression

Depression: Limited data available; efficacy results variable:

Note: In the management of depression in children and adolescents, if pharmacotherapy deemed necessary with/without psychotherapeutic interventions, an SSRI should be used first-line; citalopram is an alternative SSRI option for patients in which fluoxetine is not an option (Ref).

Children ≥7 years and Adolescents: Oral: Initial: 10 mg once daily; increase dose slowly by 10 mg/day every 1 to 2 weeks as clinically needed; reported effective dosage range: 20 to 40 mg/day (Ref).

Note: One randomized, placebo-controlled trial has shown citalopram to be effective for the treatment of depression in pediatric patients (Wagner 2004); other controlled pediatric trials have not shown benefit (Ref).

Obsessive-compulsive disorder

Obsessive-compulsive disorder (OCD): Limited data available:

Note: In the management of OCD in children and adolescents, if pharmacotherapy deemed necessary with/without psychotherapeutic interventions, an SSRI should be used first-line; a preferred agent has not been identified although fluoxetine and sertraline have FDA approval for OCD in pediatric patients (Ref).

Children ≥7 years: Oral: Initial: 2.5 to 10 mg once daily (Ref); in trials, doses were increased by 5 mg/day every 2 weeks as clinically needed; dosage range: 10 to 40 mg/day; children required higher mg/kg doses than adolescent patients (Ref).

Adolescents: Oral: 10 to 20 mg once daily (Ref); in trials, doses were increased by 10 mg/day every 2 weeks as clinically needed; dosage range: 10 to 40 mg/day (Ref).

Discontinuation of therapy: Consider planning antidepressant discontinuation for lower-stress times, recognizing non-illness-related factors could cause stress or anxiety and be misattributed to antidepressant discontinuation (Ref). Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of discontinuation syndromes (withdrawal) and allow for the detection of reemerging disease state symptoms (eg, relapse). Evidence supporting ideal taper rates after illness remission is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. After long-term (years) antidepressant treatment, WFSBP guidelines recommend tapering over 4 to 6 months, with close monitoring during and for 6 months after discontinuation. If intolerable discontinuation symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (Ref).

Switching antidepressants: Evidence for ideal antidepressant switching strategies in pediatric patients is sparse; strategies described in pediatric guidelines include a conservative approach (tapering and discontinuing the first SSRI before adding the second) and cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant). While consensus does not exist regarding which approach to utilize, it is important to note that the conservative approach runs the risk for exacerbation of symptoms or discontinuation syndrome; cross-titration may avoid these risks (Ref). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches but is contraindicated when switching to or from a monoamine oxidase inhibitor. While not as common of a strategy, a direct switch may be considered when switching to another agent in the same or similar class (eg, when switching between 2 SSRIs), when the antidepressant to be discontinued has been used for <1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, pharmacodynamics), and the degree of symptom control desired (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Specific recommendations in pediatric patients are not available; based on experience in adult patients, in mild to moderate impairment, no adjustment needed, and in severe impairment, use with caution (has not been studied).

Dosing: Liver Impairment: Pediatric

Specific recommendations in pediatric patients are not available; based on experience in adult patients, consider reduced daily doses due to increased serum concentrations and the risk of QT prolongation.

Dosing: Adult

(For additional information see "Citalopram: Drug information")

Dosage guidance:

Safety: Doses >40 mg/day are generally not recommended due to risk of QT prolongation.

Dosing: Some experts suggest a lower starting dose of 10 mg daily and gradual titration in increments of ≤10 mg, particularly in patients with anxiety who are sensitive to antidepressant-associated overstimulation effects (eg, anxiety, insomnia) (Ref).

Aggressive or agitated behavior associated with dementia

Aggressive or agitated behavior associated with dementia (off-label use): Oral: Initial: 10 mg once daily; increase to 20 mg once daily after ≥3 days. In adults ≤60 years, may further increase dose based on response and tolerability up to 30 mg/day (Ref); for adults >60 years, do not exceed the maximum dose of 20 mg/day.

Binge eating disorder

Binge eating disorder (off-label use): Oral: Initial: 20 mg once daily. In adults ≤60 years of age, may gradually increase dose based on response and tolerability at intervals ≥1 week to 40 mg once daily. Although doses up to 60 mg/day have been studied, due to safety considerations the recommended maximum dose is 40 mg/day for adults ≤60 years of age and 20 mg/day for adults >60 years (Ref).

Generalized anxiety disorder

Generalized anxiety disorder (off-label use): Oral: Initial: 10 mg once daily; may gradually increase dose based on response and tolerability in 10 mg increments at intervals ≥1 week to a maximum dose of 40 mg/day for adults ≤60 years and 20 mg/day for adults >60 years of age (Ref). Doses may be increased every 3 to 4 days if warranted in inpatient settings. Some experts suggest maintaining the initial therapeutic dose for 4 to 6 weeks to assess for efficacy before increasing further (Ref).

Major depressive disorder

Major depressive disorder (unipolar): Oral: Initial: 20 mg once daily. In adults ≤60 years of age, may gradually increase dose based on response and tolerability at intervals ≥1 week to a maximum recommended dose of 40 mg/day; for adults >60 years of age, the maximum recommended dose is 20 mg/day. Daily doses that exceeded these limits have been studied and may occasionally be warranted with additional monitoring but are generally not recommended due to safety considerations (Ref).

Obsessive-compulsive disorder

Obsessive-compulsive disorder (alternative agent) (off-label use):

Note: In order to effectively treat obsessive-compulsive disorder (OCD), selective serotonin reuptake inhibitors (SSRIs) are often used at doses exceeding the maximum dose for other indications. Some experts recommend against the use of citalopram in OCD due to risk of dose-related QTc prolongation (Ref).

Oral: Initial: 20 mg once daily. In adults ≤60 years of age, may gradually increase dose based on response and tolerability in 10 to 20 mg increments at intervals ≥1 week to a maximum dose of 40 mg/day; for adults >60 years of age, do not exceed the maximum dose of 20 mg/day (Ref). An adequate trial for assessment of effect in OCD is considered to be ≥6 weeks at maximum tolerated dose (Ref).

Panic disorder

Panic disorder (off-label use): Oral: Initial: 10 mg once daily for 3 to 7 days, then 20 mg once daily. In adults ≤60 years, may gradually increase dose based on response and tolerability in 10 to 20 mg increments at intervals ≥1 week to a maximum of 40 mg/day; for adults >60 years of age, do not exceed the maximum dose of 20 mg/day. Daily doses that exceeded these limits have been studied but are not recommended due to safety considerations (Ref). Some experts maintain dose at 20 mg for 4 weeks before considering further dose increases. May require 6 weeks at maximally tolerated dose for adequate treatment trial (Ref).

Posttraumatic stress disorder

Posttraumatic stress disorder (off-label use): Oral: Initial: 20 mg once daily. In adults ≤60 years of age, may gradually increase dose based on response and tolerability in 10 to 20 mg increments at intervals ≥1 week to a maximum dose of 40 mg once daily; for adults >60 years of age, do not exceed the maximum dose of 20 mg/day. Daily doses that exceeded these limits have been studied but are not recommended due to safety considerations (Ref).

Premature ejaculation

Premature ejaculation (off-label use): Oral: Initial: 20 mg once daily. In adults ≤60 years of age, may gradually increase dose based on response and tolerability at intervals of ≥1 week (some experts suggest 3- to 4-week titration intervals (Ref)) up to a maximum of 40 mg/day (Ref); for adults >60 years of age, do not exceed the maximum dose of 20 mg/day.

Premenstrual dysphoric disorder

Premenstrual dysphoric disorder (PMDD) (off-label use):

Continuous daily dosing regimen: Oral: Initial: 10 mg once daily; over the first month increase to usual effective dose of 20 mg once daily; in subsequent menstrual cycles, further dose increases (eg, in 10 mg increments per menstrual cycle) up to 40 mg/day may be necessary in some patients for optimal response (Ref).

Intermittent regimens:

Luteal phase dosing regimen: Oral: Initial: 10 mg once daily during the luteal phase of menstrual cycle only (ie, beginning therapy 14 days before anticipated onset of menstruation and continued to the onset of menses); over the first month increase to usual effective dose of 20 mg once daily during the luteal phase; in a subsequent menstrual cycle, a further increase to 30 mg/day during the luteal phase may be necessary in some patients for optimal response (Ref).

Symptom-onset dosing regimen: Oral: Initial: 10 mg once daily from the day of symptom onset until a few days after the start of menses; over the first month increase to usual effective dose of 20 mg once daily; in a subsequent menstrual cycle a further increase to 30 mg/day may be necessary in some patients for optimal response (Ref).

Social anxiety disorder

Social anxiety disorder (off-label use): Oral: Initial: 10 to 20 mg once daily. In adults ≤60 years of age, after 4 to 6 weeks may gradually increase dose based on response and tolerability in 10 to 20 mg increments at intervals ≥1 week up to maximum of 40 mg/day; for adults >60 years of age, do not exceed the maximum dose of 20 mg/day. Daily doses that exceeded these limits have been studied but are not recommended due to safety considerations (Ref).

Vasomotor symptoms associated with menopause

Vasomotor symptoms associated with menopause (alternative agent) (off-label use): Oral: Initial: 10 mg once daily; may increase dose to 20 mg once daily after 1 week. In adults ≤60 years of age, doses as high as 40 mg/day have been studied; however, doses >20 mg/day have demonstrated little additional benefit and greater adverse effects (Ref). Maximum: 40 mg/day. For adults >60 years of age, do not exceed the maximum dose of 20 mg/day.

CYP2C19 poor metabolizers: Maximum dose: 20 mg/day.

Discontinuation of therapy:When discontinuing antidepressant treatment that has lasted for ≥4 weeks, gradually taper the dose (eg, over 2 to 4 weeks) to minimize withdrawal symptoms and detect reemerging symptoms (Ref). For brief treatment (eg, 2 to 3 weeks) may taper over 1 to 2 weeks; <2 weeks treatment generally does not warrant tapering (Ref). Reasons for a slower taper (eg, over 4 weeks) include prior history of antidepressant withdrawal symptoms or high doses of antidepressants (Ref). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (Ref). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (>6 months) may benefit from tapering over >3 months (Ref). Evidence supporting ideal taper rates is limited (Ref).

Switching antidepressants: Evidence for ideal antidepressant switching strategies is limited; strategies include cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant) and direct switch (abruptly discontinuing the first antidepressant and then starting the new antidepressant at an equivalent dose or lower dose and increasing it gradually). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from an MAOI. A direct switch may be an appropriate approach when switching to another agent in the same or similar class (eg, when switching between two SSRIs), when the antidepressant to be discontinued has been used for <1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, pharmacodynamics), and the degree of symptom control desired (Ref).

Switching to or from an MAOI:

Allow 14 days to elapse between discontinuing an MAOI and initiation of citalopram.

Allow 14 days to elapse between discontinuing citalopram and initiation of an MAOI.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Note: Limited pharmacokinetic data are available in patients with severe kidney impairment and on hemodialysis (Ref).

Altered kidney function:

CrCl ≥20 mL/minute: No dosage adjustment necessary.

CrCl <20 mL/minute: Initial: 10 mg once daily; gradually titrate based on tolerability and response with close monitoring for adverse effects (eg, QT prolongation) (Ref).

Hemodialysis, intermittent (thrice weekly): Neither citalopram nor its active metabolite, desmethylcitalopram, are significantly dialyzed (1% (Ref)):

Note: An increase in sudden cardiac death in hemodialysis patients prescribed selective serotonin reuptake inhibitors (SSRIs) with higher QT-prolonging potential (citalopram, escitalopram) compared to SSRIs with lower QT-prolonging potential was observed in a retrospective cohort study (Ref). Therefore, use of an SSRI with a lower QT-prolonging potential may be preferred.

Initial: 10 mg once daily; gradually titrate based on tolerability and response with close monitoring for adverse effects (eg, QT prolongation) (Ref).

Peritoneal dialysis: Unlikely to be significantly dialyzed (highly protein bound, large Vd) (Ref):

Note: An increase in sudden cardiac death in hemodialysis patients prescribed SSRIs with higher QT-prolonging potential (citalopram, escitalopram) compared to SSRIs with lower QT-prolonging potential was observed in a retrospective cohort study (Ref). A similar risk has not been observed in patients on peritoneal dialysis (has not been studied), but use of an SSRI with a lower QT-prolonging potential may be preferred.

Initial: 10 mg once daily; gradually titrate based on tolerability and response with close monitoring for adverse effects (eg, QT prolongation) (Ref).

Dosing: Liver Impairment: Adult

The liver dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, FCCP; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.

Note: In a small, single dose pharmacokinetic study in patients with cirrhosis (Child-Turcotte-Pugh class A to C) citalopram elimination was decreased and half-life was prolonged (two-fold) (Ref). Increased exposure may contribute to increased seizure risk and QTc prolongation, which is common in cirrhosis; consider alternative agents specifically in patients at high risk for QT prolongation (Ref).

Liver impairment prior to treatment initiation:

Initial or dose titration in patients with preexisting liver cirrhosis:

Child-Turcotte-Pugh class A to C: Oral: Initial: 10 mg once daily; if necessary, may increase to a maximum dose of 20 mg/day after ≥14 days; use with caution (Ref).

Liver impairment developing in patients already receiving citalopram:

Chronic disease progression (eg, outpatient):

Progression from baseline to Child-Turcotte-Pugh class A to C: Oral:

If current dose ≤20 mg/day: No dosage adjustment necessary; use with caution (Ref).

If current dose >20mg/day: Reduce dose to a maximum of 20 mg/day (Ref). Rate of reduction (eg, rapid versus gradual) should be individualized based on patient-specific factors (eg, indication, current dose); use with caution (Ref).

Acute hepatoxicity during treatment (eg, requiring hospitalization): Oral:

If current dose ≤20 mg/day: No dosage adjustment necessary; use with caution (Ref).

If current dose >20mg/day: Reduce dose to a maximum of 20 mg/day (Ref). Rate of reduction (eg, rapid versus gradual) should be individualized based on patient-specific factors (eg, indication, current dose); use with caution (Ref).

Adverse Reactions (Significant): Considerations
Activation of mania or hypomania

Antidepressants (when used as monotherapy) may precipitate a mixed/manic episode in patients with bipolar disorder. Treatment-emergent mania or hypomania in patients with unipolar major depressive disorder (MDD) have been reported, as many cases of bipolar disorder present in episodes of MDD (Ref). In addition, treatment-emergent mania or hypomania has been described in patients receiving antidepressants, including selective serotonin reuptake inhibitors (SSRIs), for the treatment of obsessive-compulsive disorder (OCD) without a history of bipolar disorder (with or without comorbid MDD) (Ref).

Mechanism: Non–dose-related; idiosyncratic. Unclear to what extent mood switches represent an uncovering of unrecognized bipolar disorder or a more direct pharmacologic effect independent of diagnosis (Ref).

Onset: Varied; a systematic review observed that the risk of switching increased significantly within the initial 2 years of antidepressant treatment in patients with unipolar MDD receiving an antidepressant as monotherapy, but not thereafter (up to 4.6 years) (Ref). In a systematic review of patients with OCD who experienced switching, the manic/hypomanic episodes were more common within 12 weeks of antidepressant treatment initiation; however, episodes occurred up to 9 months in these patients (Ref).

Risk factors:

• Family history of bipolar disorder (Ref)

• Depressive episode with psychotic symptoms (Ref)

• Younger age at onset of depression (Ref)

• Antidepressant resistance (Ref)

• Females (Ref)

Bleeding risk

Selective serotonin reuptake inhibitors (SSRIs), including citalopram, may increase the risk of bleeding, particularly if used concomitantly with antiplatelets and/or anticoagulants. Multiple observational studies have found an association with SSRI use and a variety of bleeding complications, ranging from bruising, hematomas, petechiae, purpuric disease, and epistaxis to cerebrovascular accident, upper gastrointestinal hemorrhage, intracranial hemorrhage, postpartum hemorrhage (exposure during late gestation), vaginal hemorrhage, and perioperative bleeding, although conflicting evidence also exists (Ref).

Mechanism: Possibly via inhibition of serotonin-mediated platelet activation (inhibition of the serotonin reuptake transporter) and subsequent platelet dysfunction. Citalopram is considered to display moderate affinity for the serotonin reuptake receptor (Ref). SSRIs may also increase gastric acidity, which can increase the risk of GI bleeding (Ref).

Onset: Varied; bleeding risk is likely delayed for several weeks until SSRI-induced platelet serotonin depletion becomes clinically significant (Ref); although the onset of bleeding may be more unpredictable if patients are taking concomitant antiplatelets, anticoagulants, or nonsteroidal anti-inflammatory drugs (NSAIDs). For upper GI bleeding, some studies have found risk to be the highest in the first 28 to 30 days (Ref); whereas, another study reported a median time of onset of 25 weeks (Ref).

Risk factors:

• Concomitant use of anticoagulants and/or antiplatelets (Ref)

• Preexisting platelet dysfunction or coagulation disorders (eg, von Willebrand factor) (Ref)

• Concomitant use of NSAIDs increases the risk for upper GI bleeding (Ref)

Fragility fractures

Limited data from observational studies involving mostly older adults (≥50 years of age) suggest selective serotonin reuptake inhibitors (SSRIs) are associated with an increased risk of bone fractures (Ref). In addition, several trials and subsequent meta-analyses have found an increased risk of bone fracture with the use of SSRIs in stroke survivors (Ref).

Mechanism: Time-related; mechanism not fully elucidated; postulated to be through a direct effect by SSRIs on bone metabolism via interaction with 5-HT and osteoblast, osteocyte, and/or osteoclast activity (Ref). An increased tendency to falls may also contribute to the increased risk of fractures associated with SSRIs (Ref).

Onset: Delayed; risk appears to increase after initiation and may continue to increase with long-term use. A meta-analysis found risk of fracture increased from 2.9% over 1 year to 5.4% over 2 years; within 5 years, risk increased to 13.4% (Ref). Conversely, the increased risk of bone fracture in stroke survivors who received an SSRI (fluoxetine) was no longer statistically significant at 12 months post stroke (Ref).

Risk factors:

• Long-term use may be a risk factor (Ref)

Hyponatremia

Selective serotonin reuptake inhibitors (SSRIs) are associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH) and/or hyponatremia, including severe cases, predominantly in the elderly (Ref). Hyponatremia is reversible with discontinuation of therapy (Ref).

Mechanism: May cause SIADH via release of antidiuretic hormone (ADH) (Ref) or may cause nephrogenic SIADH by increasing the sensitivity of the kidney to ADH (Ref).

Onset: Intermediate; usually develops within the first few weeks of treatment with an SSRI (Ref).

Risk factors:

• Older age (Ref)

• Females (Ref)

• Concomitant use of diuretics (Ref)

• Low body weight (Ref)

• Lower baseline serum sodium concentration (Ref)

• Volume depletion (Ref)

• History of hyponatremia (potential risk factor) (Ref)

• Symptoms of psychosis (potential risk factor) (Ref)

Ocular effects

Selective serotonin reuptake inhibitors (SSRIs) are associated with acute angle-closure glaucoma (AACG) in case reports and a case-control study. AACG may cause symptoms including eye pain, changes in vision, swelling, and redness, which can rapidly lead to permanent blindness if not treated (Ref). In addition, SSRIs may be associated with an increased risk of cataract development (Ref).

Mechanism: AACG: Unclear; hypothesized that SSRIs may increase the intraocular pressure via serotonergic effects on ciliary body muscle activation and pupil dilation (Ref).

Risk factors:

For AACG:

• Females (Ref)

• ≥50 years of age (slight increase) (Ref)

• Hyperopia (slight increase) (Ref)

• Personal or family history of AACG (Ref)

• Inuit or Asian descent (Ref)

QT prolongation

Dose-dependent prolonged QT interval on ECG and torsades de pointes (TdP) have been reported, particularly in patients with coexisting risk factors for QT effects (Ref). Citalopram is associated with a greater effect on QTc prolongation (mean QTc increase 7.8 ms [10 to 20 mg citalopram] and 10.3 ms [20 to 40 mg citalopram]) compared to escitalopram; however, the clinical significance of citalopram’s effect on QT prolongation in patients without additional risk factors receiving usual therapeutic doses has been questioned (Ref).

Mechanism: Dose-related; citalopram is believed to cause QTc prolongation via direct blockade of the rapid potassium delayed rectifier current (IKr), encoded by the human ether-à-go-go-related gene (hERG) (Ref).

Risk factors:

In general, risk factors for drug-induced QT prolongation/TdP:

• Females (Ref)

• Age >65 years (Ref)

• Structural heart disease (eg, history of myocardial infarction or heart failure with a reduced ejection fraction) (Ref)

• History of drug-induced TdP (Ref)

• Genetic defects of cardiac ion channels (Ref)

• Congenital long QT syndrome (Ref)

• Baseline QTc interval prolongation (eg, >500 msec) or lengthening of the QTc by ≥60 msec (Ref)

• Electrolyte disturbances (eg, hypokalemia, hypocalcemia, or hypomagnesemia) (Ref)

• Bradycardia (Ref)

• Hepatic impairment (Ref)

• Kidney impairment (Ref)

• Coadministration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QT-prolonging medications (Ref)

• Substance use (Ref)

Serotonin syndrome

Serotonin syndrome has been reported and typically occurs with coadministration of multiple serotonergic drugs but can occur following a single serotonergic agent at therapeutic doses (Ref). The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (Ref) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (Ref).

Mechanism: Dose-related; overstimulation serotonin receptors by serotonergic agents (Ref).

Onset: Rapid; in the majority of cases (74%), onset occurred within 24 hours of treatment initiation, overdose, or change in dose (Ref).

Risk factors:

• Concomitant use of drugs that increase serotonin synthesis, block serotonin reuptake and/or impair serotonin metabolism (eg, monamine oxidase inhibitors [MAOIs]). Of note, concomitant use of some serotonergic agents, such as MAOIs, are contraindicated.

Sexual dysfunction

Selective serotonin reuptake inhibitors (SSRIs) are commonly associated with sexual disorder in both men and women. The following adverse reactions have been associated with SSRI use: Orgasm abnormal, anorgasmia, erectile dysfunction, and decreased libido (Ref). Priapism and decreased genital sensation have also been reported with SSRIs (Ref). The impact on sexual health may be lessened with drug holidays; in an open-label trial, patients taking an SSRI (other than fluoxetine) who were instructed to not take their medication on the weekends (n = 63) reported improved erection, ejaculation, satisfaction, and overall sexual health without significant worsening in their mental health status (Ref).

Mechanism: Dose-related (Ref); increases in serotonin may affect other hormones and neurotransmitters involved in sexual function; in particular, testosterone's effect on sexual arousal and dopamine's role in achieving orgasm (Ref).

Risk factors:

• Depression (sexual dysfunction is commonly associated with depression; SSRI-associated sexual dysfunction may be difficult to differentiate in treated patients) (Ref)

Suicidal thinking and behavior

Antidepressants are associated with an increased risk of suicidal ideation and suicidal tendencies in pediatric and young adult patients (18 to 24 years of age) in short-term studies. In adults >24 years of age, short-term studies did not show an increased risk of suicidal thinking and behavior, and in older adults ≥65 years of age a decreased risk was observed. Although data have yielded inconsistent results regarding the association of antidepressants and risk of suicide, particularly among adults, collective evidence shows a trend of an elevated risk of suicidality in younger age groups (Ref). Of note, the risk of a suicide attempt is inherent in major depression and may persist until remission occurs.

Mechanism: Not established; one of several postulated mechanisms is antidepressants may energize suicidal patients to act on impulses; another suggests that antidepressants may produce a worsening of depressive symptoms leading to the emergence of suicidal thoughts and actions (Ref).

Onset: Varied; increased risk observed in short-term studies (ie, <4 months) in pediatric and young adults; it is unknown whether this risk extends to longer-term use (ie, >4 months).

Risk factors:

• Children and adolescents (Ref)

• Depression (risk of suicide is associated with major depression and may persist until remission occurs)

Withdrawal syndrome

Withdrawal syndrome, consisting of both somatic symptoms (eg, dizziness, chills, light-headedness, vertigo, 'shock-like' sensations, paresthesia, fatigue, headache, nausea, tremor, diarrhea, visual disturbances) and psychological symptoms (eg, anxiety, agitation, confusion, insomnia, irritability, mania) have been reported, primarily following abrupt discontinuation. Withdrawal symptoms may also occur following gradual tapering (Ref).

Mechanism: Withdrawal; due to reduced availability of serotonin in the CNS with decreasing levels of the selective serotonin reuptake inhibitor (SSRI). Other neurotransmission systems, including increased glutamine and dopamine, may also be affected, as well as the hypothalamic-pituitary-adrenal axis (Ref).

Onset: Intermediate; expected onset is 1 to 10 days (following either abrupt or tapered discontinuation) (Ref).

Risk factors:

• Abrupt discontinuation (rather than dose taper) or tapering the antidepressant too quickly (Ref)

• Drugs with a half-life <24 hours (eg, paroxetine, venlafaxine) (Ref)

• Higher doses (Ref)

• Longer duration of treatment (eg, ≥4 weeks) (Ref)

• Prior history of antidepressant withdrawal symptoms (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Dermatologic: Diaphoresis (11%)

Gastrointestinal: Nausea (21%), xerostomia (20%)

Nervous system: Drowsiness (18%; literature suggests incidence occurs less frequently in children and adolescents compared to adults (Ref)), insomnia (15%)

1% to 10%:

Cardiovascular: Bradycardia (1%), hypotension (≥1%), orthostatic hypotension (≥1%), prolonged QT interval on ECG (2%) (table 1), tachycardia (≥1%)

Citalopram: Adverse Reaction: Prolonged QT Interval on ECG

Drug (Citalopram)

Placebo

Number of Patients (Citalopram)

Number of Patients (Placebo)

2%

1%

802

241

Dermatologic: Pruritus (≥1%), skin rash (≥1%)

Endocrine & metabolic: Amenorrhea (≥1%), decreased libido (1% to 4%) (table 2), weight gain (≥1%), weight loss (≥1%)

Citalopram: Adverse Reaction: Decreased Libido

Drug (Citalopram)

Placebo

Population

Number of Patients (Citalopram)

Number of Patients (Placebo)

1%

N/A

Females

638

N/A

4%

<1%

Males

425

194

2%

<1%

Males and females

1,063

446

Gastrointestinal: Abdominal pain (3%), anorexia (4%), diarrhea (8%), dysgeusia (≥1%), dyspepsia (5%), flatulence (≥1%), increased appetite (≥1%), sialorrhea (≥1%), vomiting (4%; literature suggests incidence is higher in adolescents compared to adults and is two- to threefold higher in children compared to adults (Ref))

Genitourinary: Dysmenorrhea (3%), ejaculatory disorder (6%), erectile dysfunction (3%) (table 3) (table 4), polyuria (≥1%)

Citalopram: Adverse Reaction: Ejaculatory Disorder

Drug (Citalopram)

Placebo

Number of Patients (Citalopram)

Number of Patients (Placebo)

6%

1%

1,063

446

Citalopram: Adverse Reaction: Erectile Dysfunction

Drug (Citalopram)

Placebo

Number of Patients (Citalopram)

Number of Patients (Placebo)

3%

<1%

425

194

Nervous system: Agitation (3%), amnesia (≥1%), anxiety (4%), apathy (≥1%), confusion (≥1%), depression (≥1%), fatigue (5%), lack of concentration (≥1%), migraine (≥1%), paresthesia (≥1%), tremor (8%), yawning (2%)

Neuromuscular & skeletal: Arthralgia (2%), myalgia (2%)

Ophthalmic: Accommodation disturbance (≥1%)

Respiratory: Cough (≥1%), rhinitis (5%), sinusitis (3%), upper respiratory tract infection (5%)

Miscellaneous: Fever (2%)

<1%:

Cardiovascular: Acute myocardial infarction, angina pectoris, atrial fibrillation, bundle branch block, extrasystoles, flushing, heart failure, hypertension, ischemic heart disease, peripheral edema, phlebitis, pulmonary embolism, syncope

Dermatologic: Acne vulgaris, alopecia, cellulitis, dermatitis, eczema, hypertrichosis, hypohidrosis, psoriasis, skin discoloration, skin photosensitivity, urticaria, xeroderma

Endocrine & metabolic: Altered serum glucose, dehydration, galactorrhea not associated with childbirth, goiter, gynecomastia, hot flash, hypoglycemia, hypokalemia, hyponatremia (literature suggests incidence of hyponatremia among SSRIs ranges from <1% to as high as 32% (Ref)) (Ref), hypothyroidism, increased libido, increased thirst, obesity

Gastrointestinal: Bruxism, cholecystitis, cholelithiasis, colitis, diverticulitis of the gastrointestinal tract, duodenal ulcer, dysphagia, eructation, esophagitis, gastric ulcer, gastritis, gastroenteritis, gastroesophageal reflux disease, gingival hemorrhage, gingivitis, glossitis, hemorrhoids, hiccups, melanosis, pruritus ani, stomatitis

Genitourinary: Breast hypertrophy, dysuria, hematuria, mastalgia, oliguria, urinary incontinence, urinary retention, vaginal hemorrhage

Hematologic & oncologic: Anemia, disorder of hemostatic components of blood, hypochromic anemia, leukocytosis, leukopenia, lymphadenopathy, lymphocytopenia, lymphocytosis, purpuric disease

Hepatic: Hepatitis, hyperbilirubinemia, increased liver enzymes, increased serum alkaline phosphatase, jaundice

Hypersensitivity: Facial edema

Nervous system: Abnormal gait, aggressive behavior, ataxia, catatonia, cerebrovascular accident, delusion, depersonalization, drug dependence, emotional lability, euphoria, extrapyramidal reaction, hallucination, hyperesthesia, hypertonia, hypoesthesia, involuntary muscle movements, myasthenia, neuralgia, nightmares, panic attack, paranoid ideation, psychosis, rigors, seizure, serotonin syndrome, stupor, transient ischemic attacks, vertigo

Neuromuscular & skeletal: Arthritis, bursitis, dystonia, hyperkinetic muscle activity, hypokinesia, lower limb cramp, osteoporosis, skeletal pain

Ophthalmic: Abnormal lacrimation, blepharoptosis, cataract, conjunctivitis, diplopia, dry eye syndrome, eye pain, keratitis, mydriasis, photophobia

Otic: Tinnitus

Renal: Nephrolithiasis, pyelonephritis, renal pain

Respiratory: Asthma, bronchitis, bronchospasm, dyspnea, epistaxis, flu-like symptoms, laryngitis, pneumonia, pneumonitis

Postmarketing:

Cardiovascular: Chest pain, Raynaud disease (Ref), thrombosis, torsades de pointes (Ref), ventricular arrhythmia

Dermatologic: Ecchymoses, erythema multiforme, toxic epidermal necrolysis

Endocrine & metabolic: Hyperprolactinemia, SIADH (Ref)

Gastrointestinal: Gastrointestinal hemorrhage (Ref), pancreatitis

Genitourinary: Abnormal organism (Ref), anorgasmia (Ref), priapism (including clitoral priapism) (Ref), sexual difficulty (decreased genital sensation) (Ref), sexual disorder (including persistent post SSRI) (Ref)

Hematologic & oncologic: Hemolytic anemia, hypoprothrombinemia, thrombocytopenia (Ref)

Hepatic: Hepatic necrosis

Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction

Nervous system: Akathisia, anosmia (including hyposmia), choreoathetosis, delirium, hyperactive behavior (including restlessness occurring in children at a two- to threefold higher incidence compared to adolescents (Ref)), mania (Ref), myoclonus, neuroleptic malignant syndrome (Ref), suicidal ideation (Ref), suicidal tendencies (Ref), withdrawal syndrome (Ref)

Neuromuscular & skeletal: Dyskinesia (Ref), rhabdomyolysis

Ophthalmic: Acute angle-closure glaucoma (Ref), nystagmus disorder

Renal: Acute kidney injury

Contraindications

Hypersensitivity (including angioedema, anaphylaxis) to citalopram or any component of the formulation; use of monoamine oxidase inhibitors (MAOIs) intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either citalopram or the MAOI); initiation of citalopram in a patient receiving IV methylene blue; concomitant use with pimozide.

Note: Although citalopram is contraindicated per manufacturer labeling when used in combination with linezolid, new evidence suggests that the combination is unlikely to cause serotonin syndrome (0.06% to 3% risk), and therefore these agents can be administered concomitantly when necessary. Monitor patients on this combination; average duration of serotonin toxicity is ~4 days; however, risks may be greater with longer durations of concurrent therapy. Educate patients on the signs and symptoms of serotonin syndrome (Bai 2022; Butterfield 2012; Karkow 2017; Kufel 2023; Narita 2007; Taylor 2006).

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Canadian labeling: Additional contraindications (not in US labeling): Known QT interval prolongation or congenital long QT syndrome

Warnings/Precautions

Concerns related to adverse effects:

• CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.

Disease-related concerns:

• Bariatric surgery: Presurgical assessment of the indication for use, symptoms, and goals of therapy should be documented to enable postsurgical assessment. Data from one patient in a small pharmacokinetic study showed an approximate decrease in citalopram exposure of 50% early postsurgery (eg, <30 days); overall selective serotonin reuptake inhibitors (SSRIs) had wide interpatient variability (Hamad 2012). Monitor for continued efficacy after bariatric surgery and consider switching to an alternate medication if symptoms worsen.

• Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and half-life and plasma concentrations are increased.

• Renal impairment: Use with caution in patients with severe renal impairment.

• Seizure disorders: Use with caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcohol use disorder.

Special populations:

• CYP2C19 poor metabolizers: Citalopram exposure and maximum concentrations are increased in CYP2C19 poor metabolizers; a dose reduction may be required.

• Older adult: Pharmacokinetics are altered in patients >60 years of age.

• Pediatric: Citalopram is not FDA-approved for use in children; however, if used, monitor weight and growth regularly during therapy due to the potential for decreased appetite and weight loss with SSRI use.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral, as hydrobromide:

Generic: 30 mg

Solution, Oral, as hydrobromide:

Generic: 10 mg/5 mL (10 mL [DSC], 240 mL, 473 mL); 20 mg/10 mL (10 mL)

Tablet, Oral, as hydrobromide:

CeleXA: 10 mg

CeleXA: 20 mg, 40 mg [scored]

Generic: 10 mg, 20 mg, 40 mg

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (Citalopram Hydrobromide Oral)

30 mg (per each): $6.48

Solution (Citalopram Hydrobromide Oral)

10 mg/5 mL (per mL): $0.49 - $0.98

Tablets (CeleXA Oral)

10 mg (per each): $10.89

20 mg (per each): $11.35

40 mg (per each): $11.85

Tablets (Citalopram Hydrobromide Oral)

10 mg (per each): $2.43 - $2.58

20 mg (per each): $2.53 - $2.69

40 mg (per each): $2.64 - $2.78

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral, as hydrobromide:

CeleXA: 20 mg, 40 mg

CTP 30: 30 mg

Generic: 10 mg, 20 mg, 30 mg, 40 mg

Administration: Pediatric

Oral: May be administered without regard to meals.

Administration: Adult

Oral: May be administered without regard to food.

Storage/Stability

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

Citalopram capsules: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215428s002lbl.pdf#page=24

Citalopram tablets: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020822s054lbl.pdf#page=22

Use

Treatment of depression (FDA approved in adults); has also been used to treat obsessive-compulsive disorder (OCD).

Medication Safety Issues
Sound-alike/look-alike issues:

CeleXA may be confused with CeleBREX, Cerebyx, Ranexa, ZyPREXA

Citalopram may be confused with escitalopram

Older Adult: High-Risk Medication:

Beers Criteria: Selective Serotonin Reuptake Inhibitors (SSRIs) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older because of the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).

Citalopram is identified in the Screening Tool of Older Person's Prescriptions (STOPP) criteria as a potentially inappropriate medication in older adults (≥65 years of age) with a history of recurrent falls due to an increased risk of falls. In addition, some disease states of concern include QTc prolongation, hyponatremia, and recent or current bleeding (O’Mahony 2023).

Metabolism/Transport Effects

Substrate of CYP2C19 (Major with inhibitors), CYP2C19 (Minor with inducers), CYP2D6 (Minor), CYP3A4 (Major with inducers), CYP3A4 (Minor with inhibitors); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP2D6 (Weak);

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program

Abciximab: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Abrocitinib: Agents with Antiplatelet Effects may increase antiplatelet effects of Abrocitinib. Risk X: Avoid

Acalabrutinib: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Agents with Blood Glucose Lowering Effects: Selective Serotonin Reuptake Inhibitor may increase hypoglycemic effects of Agents with Blood Glucose Lowering Effects. Risk C: Monitor

Alcohol (Ethyl): May increase adverse/toxic effects of Selective Serotonin Reuptake Inhibitor. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol. Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors. Risk D: Consider Therapy Modification

Almotriptan: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Alosetron: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Amisulpride (Oral): May increase QTc-prolonging effects of QT-prolonging Agents (Moderate Risk). Risk C: Monitor

Amphetamines: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust doses as needed. Risk C: Monitor

Anagrelide: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Anticoagulants (Miscellaneous Agents): Antidepressants with Antiplatelet Effects may increase anticoagulant effects of Anticoagulants (Miscellaneous Agents). Risk C: Monitor

Antiemetics (5HT3 Antagonists): May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Antiplatelet Agents (P2Y12 Inhibitors): Agents with Antiplatelet Effects may increase antiplatelet effects of Antiplatelet Agents (P2Y12 Inhibitors). Risk C: Monitor

Antipsychotic Agents: Serotonergic Agents (High Risk) may increase adverse/toxic effects of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Risk C: Monitor

Aspirin: Selective Serotonin Reuptake Inhibitor may increase antiplatelet effects of Aspirin. Risk C: Monitor

Brexanolone: Selective Serotonin Reuptake Inhibitor may increase CNS depressant effects of Brexanolone. Risk C: Monitor

Bromopride: May increase adverse/toxic effects of Selective Serotonin Reuptake Inhibitor. Risk X: Avoid

BuPROPion: May increase adverse/toxic effects of Citalopram. BuPROPion may increase serum concentration of Citalopram. Management: Initiate citalopram at the lower end of the normal dose range in patients receiving bupropion and consider limiting the maximum citalopram adult dose to 20 mg/day during concomitant bupropion treatment. Monitor for citalopram toxicities. Risk D: Consider Therapy Modification

BusPIRone: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Caplacizumab: Agents with Antiplatelet Effects may increase adverse/toxic effects of Caplacizumab. Specifically, the risk of bleeding may be increased. Risk C: Monitor

Cimetidine: May increase serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with cimetidine. Patients using this combination should be monitored closely for evidence of citalopram toxicity (eg, serotonin syndrome, QT prolongation). Risk D: Consider Therapy Modification

CloZAPine: May increase QTc-prolonging effects of Citalopram. CloZAPine may increase serotonergic effects of Citalopram. This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, serotonin syndrome, and neuroleptic malignant syndrome when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Collagenase (Systemic): Agents with Antiplatelet Effects may increase adverse/toxic effects of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. Risk C: Monitor

Cyclobenzaprine: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

CYP2C19 Inhibitors (Moderate): May increase serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor. Patients using this combination should be monitored closely for evidence of citalopram toxicity (eg, serotonin syndrome, QT prolongation). Risk D: Consider Therapy Modification

CYP3A4 Inducers (Strong): May decrease serum concentration of Citalopram. Risk C: Monitor

Cyproheptadine: May decrease therapeutic effects of Selective Serotonin Reuptake Inhibitor. Risk C: Monitor

Dabrafenib: May increase QTc-prolonging effects of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Dapoxetine: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated. Risk X: Avoid

Dasatinib: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Deoxycholic Acid: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Desmopressin: Hyponatremia-Associated Agents may increase hyponatremic effects of Desmopressin. Risk C: Monitor

Dexmethylphenidate-Methylphenidate: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Dextromethorphan: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Direct Oral Anticoagulants (DOACs): Antidepressants with Antiplatelet Effects may increase anticoagulant effects of Direct Oral Anticoagulants (DOACs). Risk C: Monitor

Domperidone: QT-prolonging Agents (Moderate Risk) may increase QTc-prolonging effects of Domperidone. Risk X: Avoid

DULoxetine: Selective Serotonin Reuptake Inhibitor may increase serotonergic effects of DULoxetine. This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitor may increase antiplatelet effects of DULoxetine. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding. Risk C: Monitor

Eletriptan: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Encorafenib: Citalopram may increase QTc-prolonging effects of Encorafenib. Encorafenib may decrease serum concentration of Citalopram. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and reduced citalopram concentrations and efficacy when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Epinephrine (Racemic): Selective Serotonin Reuptake Inhibitor may increase adverse/toxic effects of Epinephrine (Racemic). Risk X: Avoid

Ergot Derivatives: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Escitalopram: May increase QTc-prolonging effects of Citalopram. Escitalopram may increase serotonergic effects of Citalopram. This could result in serotonin syndrome. Citalopram may increase antiplatelet effects of Escitalopram. Risk X: Avoid

Esomeprazole: May increase serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with esomeprazole. Patients using this combination should be monitored closely for evidence of citalopram toxicity (eg, serotonin syndrome, QT prolongation, etc.). Risk D: Consider Therapy Modification

Fenfluramine: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Risk C: Monitor

Fexinidazole: May increase QTc-prolonging effects of Citalopram. Fexinidazole may increase serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with fexinidazole, which is a moderate CYP2C19 inhibitor. Monitor for citalopram toxicity (eg, serotonin syndrome), QTc prolongation, and arrhythmias (including torsades de pointes). Risk D: Consider Therapy Modification

Fluconazole: May increase QTc-prolonging effects of Citalopram. Fluconazole may increase serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with fluconazole, which is a strong CYP2C19 inhibitor. Patients using this combination should be monitored closely for citalopram toxicities, including serotonin syndrome and QT prolongation. Risk D: Consider Therapy Modification

Fluorouracil Products: May increase QTc-prolonging effects of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

FLUoxetine: Citalopram may increase serotonergic effects of FLUoxetine. This could result in serotonin syndrome. Citalopram may increase antiplatelet effects of FLUoxetine. FLUoxetine may increase serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day. Monitor for signs and symptoms of bleeding, QTc interval prolongation, or serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor) if combined. Risk D: Consider Therapy Modification

FluvoxaMINE: Citalopram may increase serotonergic effects of FluvoxaMINE. This could result in serotonin syndrome. Citalopram may increase antiplatelet effects of FluvoxaMINE. FluvoxaMINE may increase serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day. Monitor for signs and symptoms of bleeding, QTc prolongation, or serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor) if combined. Risk D: Consider Therapy Modification

Fondaparinux: Antidepressants with Antiplatelet Effects may increase anticoagulant effects of Fondaparinux. Risk C: Monitor

Gepirone: May increase QTc-prolonging effects of QT-prolonging Antidepressants (Moderate Risk). Gepirone may increase serotonergic effects of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome. Risk C: Monitor

Gilteritinib: May decrease therapeutic effects of Citalopram. Citalopram may increase QTc-prolonging effects of Gilteritinib. Management: Avoid use of this combination if possible. If use is necessary, monitor for reduced response to citalopram and for QTc prolongation and arrhythmias. Patients with other risk factors may be at greater risk for these serious toxicities. Risk D: Consider Therapy Modification

Glycoprotein IIb/IIIa Inhibitors: Agents with Antiplatelet Effects may increase antiplatelet effects of Glycoprotein IIb/IIIa Inhibitors. Risk C: Monitor

Haloperidol: QT-prolonging Antidepressants (Moderate Risk) may increase QTc-prolonging effects of Haloperidol. Haloperidol may increase serotonergic effects of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk. Risk C: Monitor

Heparin: Antidepressants with Antiplatelet Effects may increase anticoagulant effects of Heparin. Risk C: Monitor

Heparins (Low Molecular Weight): Antidepressants with Antiplatelet Effects may increase anticoagulant effects of Heparins (Low Molecular Weight). Risk C: Monitor

Herbal Products with Anticoagulant/Antiplatelet Effects: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Hydroxychloroquine: May increase QTc-prolonging effects of Citalopram. Citalopram may increase hypoglycemic effects of Hydroxychloroquine. Risk C: Monitor

Ibritumomab Tiuxetan: Agents with Antiplatelet Effects may increase antiplatelet effects of Ibritumomab Tiuxetan. Risk C: Monitor

Ibrutinib: Agents with Antiplatelet Effects may increase adverse/toxic effects of Ibrutinib. Specifically, the risk of bleeding and hemorrhage may be increased. Risk C: Monitor

Inotersen: Agents with Antiplatelet Effects may increase adverse/toxic effects of Inotersen. Specifically, the risk of bleeding may be increased. Risk C: Monitor

Ioflupane I 123: Coadministration of Selective Serotonin Reuptake Inhibitor and Ioflupane I 123 may alter diagnostic results. Risk C: Monitor

Lasmiditan: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Levoketoconazole: QT-prolonging Agents (Moderate Risk) may increase QTc-prolonging effects of Levoketoconazole. Risk X: Avoid

Levomethadone: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Limaprost: May increase adverse/toxic effects of Agents with Antiplatelet Effects. Specifically, the risk of bleeding may be increased. Risk C: Monitor

Linezolid: May increase serotonergic effects of Selective Serotonin Reuptake Inhibitor. This could result in serotonin syndrome. Risk X: Avoid

Lofexidine: May increase QTc-prolonging effects of Citalopram. Citalopram may increase QTc-prolonging effects of Lofexidine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Metaxalone: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Methylene Blue: Selective Serotonin Reuptake Inhibitor may increase serotonergic effects of Methylene Blue. This could result in serotonin syndrome. Risk X: Avoid

Metoclopramide: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Consider monitoring for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Miscellaneous Antiplatelets: Agents with Antiplatelet Effects may increase antiplatelet effects of Miscellaneous Antiplatelets. Risk C: Monitor

Mivacurium: Selective Serotonin Reuptake Inhibitor may increase serum concentration of Mivacurium. Risk C: Monitor

Monoamine Oxidase Inhibitors (Antidepressant): Selective Serotonin Reuptake Inhibitor may increase serotonergic effects of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. Risk X: Avoid

Nefazodone: May increase serotonergic effects of Selective Serotonin Reuptake Inhibitor. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Selective Serotonin Reuptake Inhibitor may increase antiplatelet effects of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may decrease therapeutic effects of Selective Serotonin Reuptake Inhibitor. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents (Nonselective): Selective Serotonin Reuptake Inhibitor may increase antiplatelet effects of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may decrease therapeutic effects of Selective Serotonin Reuptake Inhibitor. Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk. Risk D: Consider Therapy Modification

Nonsteroidal Anti-Inflammatory Agents (Topical): May increase antiplatelet effects of Selective Serotonin Reuptake Inhibitor. Risk C: Monitor

Obinutuzumab: Agents with Antiplatelet Effects may increase adverse/toxic effects of Obinutuzumab. Specifically, the risk of bleeding may be increased. Management: Consider avoiding coadministration of obinutuzumab and agents with antiplatelet effects, especially during the first cycle of obinutuzumab therapy. Risk D: Consider Therapy Modification

Omeprazole: May increase serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with omeprazole. Monitor for evidence of citalopram toxicity (eg, serotonin syndrome, QT prolongation) in patients receiving this combination. Risk D: Consider Therapy Modification

Ondansetron: May increase QTc-prolonging effects of QT-prolonging Antidepressants (Moderate Risk). Ondansetron may increase serotonergic effects of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome when these agents are combined. Patients with additional risk factors for QTc prolongation or serotonin syndrome may be at even higher risk. Risk C: Monitor

Opioid Agonists (metabolized by CYP3A4 and CYP2D6): May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Opioid Agonists (metabolized by CYP3A4): May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Opioid Agonists: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Opipramol: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Oxitriptan: Serotonergic Agents (High Risk) may increase serotonergic effects of Oxitriptan. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

OxyCODONE: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Pentamidine (Systemic): May increase QTc-prolonging effects of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Pentosan Polysulfate Sodium: Agents with Antiplatelet Effects may increase adverse/toxic effects of Pentosan Polysulfate Sodium. Specifically, the risk of hemorrhage may be increased. Risk C: Monitor

Perhexiline: Citalopram may increase serum concentration of Perhexiline. Risk C: Monitor

Pimozide: May increase QTc-prolonging effects of QT-prolonging Agents (Moderate Risk). Risk X: Avoid

Piperaquine: QT-prolonging Agents (Moderate Risk) may increase QTc-prolonging effects of Piperaquine. Risk X: Avoid

Pirtobrutinib: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Psilocybin: Antidepressants may decrease therapeutic effects of Psilocybin. Risk C: Monitor

QT-prolonging Agents (Highest Risk): May increase QTc-prolonging effects of Citalopram. Risk X: Avoid

QT-prolonging Antidepressants (Moderate Risk): Citalopram may increase QTc-prolonging effects of QT-prolonging Antidepressants (Moderate Risk). Citalopram may increase serotonergic effects of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome. Citalopram may increase serum concentration of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

QT-prolonging Antipsychotics (Moderate Risk): May increase QTc-prolonging effects of QT-prolonging Antidepressants (Moderate Risk). QT-prolonging Antipsychotics (Moderate Risk) may increase serotonergic effects of QT-prolonging Antidepressants (Moderate Risk). This could result in serotonin syndrome. Management: Monitor for QTc interval prolongation, ventricular arrhythmias, and serotonin syndrome/serotonin toxicity (SS/ST) or NMS when these agents are combined. Patients with additional risk factors for QTc prolongation or SS/ST may be at even higher risk. Risk C: Monitor

QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May increase QTc-prolonging effects of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

QT-Prolonging Inhalational Anesthetics (Moderate Risk): May increase QTc-prolonging effects of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

QT-prolonging Kinase Inhibitors (Moderate Risk): QT-prolonging Antidepressants (Moderate Risk) may increase QTc-prolonging effects of QT-prolonging Kinase Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

QT-prolonging Miscellaneous Agents (Moderate Risk): QT-prolonging Antidepressants (Moderate Risk) may increase QTc-prolonging effects of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): Citalopram may increase QTc-prolonging effects of QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase serum concentration of Citalopram. Risk C: Monitor

QT-prolonging Quinolone Antibiotics (Moderate Risk): May increase QTc-prolonging effects of QT-prolonging Antidepressants (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): Citalopram may increase QTc-prolonging effects of QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor

Ramosetron: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Rasagiline: Selective Serotonin Reuptake Inhibitor may increase serotonergic effects of Rasagiline. This could result in serotonin syndrome. Risk X: Avoid

Safinamide: May increase serotonergic effects of Selective Serotonin Reuptake Inhibitor. This could result in serotonin syndrome. Risk X: Avoid

Selective Serotonin Reuptake Inhibitor: Citalopram may increase serotonergic effects of Selective Serotonin Reuptake Inhibitor. This could result in serotonin syndrome. Citalopram may increase antiplatelet effects of Selective Serotonin Reuptake Inhibitor. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding. Risk C: Monitor

Selegiline: Selective Serotonin Reuptake Inhibitor may increase serotonergic effects of Selegiline. This could result in serotonin syndrome. Risk X: Avoid

Selumetinib: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Serotonergic Agents (High Risk, Miscellaneous): May increase serotonergic effects of Selective Serotonin Reuptake Inhibitor. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Serotonergic Non-Opioid CNS Depressants: Selective Serotonin Reuptake Inhibitor may increase serotonergic effects of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Serotonergic Opioids (High Risk): May increase serotonergic effects of Selective Serotonin Reuptake Inhibitor. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined. Risk C: Monitor

Serotonin 5-HT1D Receptor Agonists (Triptans): May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Serotonin/Norepinephrine Reuptake Inhibitor: Selective Serotonin Reuptake Inhibitor may increase serotonergic effects of Serotonin/Norepinephrine Reuptake Inhibitor. This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitor may increase antiplatelet effects of Serotonin/Norepinephrine Reuptake Inhibitor. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding. Risk C: Monitor

Sertindole: May increase QTc-prolonging effects of QT-prolonging Agents (Moderate Risk). Risk X: Avoid

St John's Wort: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Syrian Rue: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Thiazide and Thiazide-Like Diuretics: Selective Serotonin Reuptake Inhibitor may increase hyponatremic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Thioridazine: QT-prolonging Agents (Moderate Risk) may increase QTc-prolonging effects of Thioridazine. Risk X: Avoid

Thrombolytic Agents: Agents with Antiplatelet Effects may increase adverse/toxic effects of Thrombolytic Agents. Specifically, the risk of bleeding may be increased. Risk C: Monitor

Thyroid Products: Selective Serotonin Reuptake Inhibitor may decrease therapeutic effects of Thyroid Products. Thyroid product dose requirements may be increased. Risk C: Monitor

Tilidine: May increase serotonergic effects of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined. Risk C: Monitor

Tipranavir: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

TraMADol: May increase adverse/toxic effects of Selective Serotonin Reuptake Inhibitor. Specifically, the risk for serotonin syndrome/serotonin toxicity and seizures may be increased. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and seizures when these agents are combined. Risk C: Monitor

Tricyclic Antidepressants: May increase serotonergic effects of Citalopram. Tricyclic Antidepressants may increase serum concentration of Citalopram. Citalopram may increase serum concentration of Tricyclic Antidepressants. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA and citalopram concentrations/effects. Risk C: Monitor

Vasopressin: Drugs Suspected of Causing SIADH may increase therapeutic effects of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. Risk C: Monitor

Venlafaxine: Selective Serotonin Reuptake Inhibitor may increase antiplatelet effects of Venlafaxine. Selective Serotonin Reuptake Inhibitor may increase serotonergic effects of Venlafaxine. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding. Risk C: Monitor

Vitamin E (Systemic): May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Vitamin K Antagonists: Antidepressants with Antiplatelet Effects may increase anticoagulant effects of Vitamin K Antagonists. Risk C: Monitor

Volanesorsen: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Vonoprazan: May increase serum concentration of Citalopram. Risk C: Monitor

Voriconazole: Citalopram may increase QTc-prolonging effects of Voriconazole. Voriconazole may increase serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day if used with voriconazole, which is a moderate CYP2C19 inhibitor. Monitor for citalopram toxicity (eg, serotonin syndrome), QTc prolongation, and arrhythmias (including torsades de pointes). Risk D: Consider Therapy Modification

Zanubrutinib: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Ziprasidone: May increase QTc-prolonging effects of Citalopram. Ziprasidone may increase serotonergic effects of Citalopram. This could result in serotonin syndrome. Risk X: Avoid

Dietary Considerations

May be taken without regard to food.

Reproductive Considerations

Evaluate pregnancy status prior to initiating treatment in patients who could become pregnant. Treatment should not be withheld, but pharmacologic management may vary based on reproductive status, severity of illness, and history of antidepressant response (ACOG 2023; WFSBP [Dodd 2018]). When treating depression, anxiety, obsessive-compulsive disorder, or post-traumatic stress disorder, selective serotonin reuptake inhibitors (SSRIs) are preferred for use prior to conception in patients who are treatment naive or who do not have a history of effective treatment. Patients effectively treated may continue their current medication when planning a pregnancy unless contraindications exist (BAP [McAllister-Williams 2017]). Management of mental health conditions in patients who could become pregnant should be based on a shared decision-making process that considers the possibility of pregnancy during treatment (ACOG 2023; BAP [McAllister-Williams 2017]; CANMAT [MacQueen 2016]).

Citalopram is also used off label for the treatment of premenstrual dysphoric disorder. Symptom-onset dosing, which is initiated on the day of symptom onset and continued until after the start of menses, may be beneficial in patients attempting to conceive (Lanza di Scalea 2019, Ravindran 2007).

Amenorrhea has been reported following use of citalopram. SSRI use may cause hyperprolactinemia and rarely changes in thyroid function, both of which can be associated with menstrual irregularities. Depression is also associated with menstrual changes (Padda 2021).

Some studies suggest SSRIs may impair semen parameters, including the motility of spermatozoa; use of other treatments may be preferred in male patients planning a pregnancy (ISSM [Althof 2014]; Sylvester 2019). SSRIs are associated with an increased risk of sexual dysfunction (Tarchi 2023). Citalopram may delay ejaculation and is used off label for the treatment of premature ejaculation (ISSM [Althof 2014]; Sathianathen 2021).

Pregnancy Considerations

Citalopram and its metabolites cross the human placenta (Paulzen 2017).

As a class, selective serotonin reuptake inhibitors (SSRIs) have been evaluated extensively in pregnant patients. Studies focusing on newborn outcomes following first trimester exposure often have inconsistent results. Overall, an increased risk of major congenital malformations has not been observed with citalopram when considering differences in study design and confounders; data evaluating the risk of specific defects are inconclusive (ACOG 2023; Anderson 2020; BAP [McAllister-Williams 2017]; Biffi 2020; Fitton 2020; Gao 2018; Lebin 2022).

Adverse effects in the newborn following SSRI exposure in the third trimester include neonatal adaptation syndrome and persistent pulmonary hypertension of the newborn. Neonatal adaptation syndrome can occur shortly after birth and typically resolves within 2 weeks. Mechanisms of neonatal adaptation syndrome are not well understood but may be due to either SSRI toxicity or withdrawal. Reducing the dose or discontinuing the SSRI prior to delivery to reduce the risk of neonatal adaptation syndrome is not recommended (ACOG 2023). Symptoms can include apnea, constant crying, cyanosis, feeding difficulty, hyperreflexia, hypo- or hypertonia, hypoglycemia, irritability, jitteriness, respiratory distress, seizures, temperature instability, tremor, and vomiting. Prolonged hospitalization, respiratory support, or tube feedings may be required.

Persistent pulmonary hypertension of the newborn is a rare complication of SSRI use during pregnancy with symptoms of respiratory distress within the first hours of life and an increased risk of neonatal mortality (ACOG 2023). Monitoring of infants exposed to SSRIs late in pregnancy is recommended (Masarwa 2019; Ng 2019). Data related to the long-term effects of in utero SSRI exposure on infant neurodevelopment and behavior are limited (CANMAT [MacQueen 2016]; Lebin 2022).

SSRIs may increase the risk of bleeding. Exposure late in pregnancy is associated with less than a 2-fold increase in postpartum hemorrhage. The clinical significance of this is uncertain (BAP [McAllister-Williams 2017]; Lebin 2022). Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of citalopram may be altered. In addition, changes in maternal CYP2D6 and CYP2C19 activity also influence citalopram and metabolite concentrations. Close clinical monitoring as pregnancy progresses and therapeutic drug monitoring to detect patterns of changing plasma concentrations is recommended to assist dose adjustment when needed (Paulzen 2017; Schoretsanitis 2020).

Untreated and undertreated mental health conditions are associated with adverse pregnancy outcomes. Untreated or undertreated depression is associated with preterm birth, low birth weight (LBW), preeclampsia, postpartum depression, and impaired infant attachment (associated with long-term developmental effects). Anxiety disorders during pregnancy are associated with LBW, preterm birth, and adverse behavioral outcomes in the offspring. Discontinuing effective medications during pregnancy increases the risk of symptom relapse. Management should be made as part of a shared decision-making process (ACOG 2023). Patients effectively treated for depression, anxiety, obsessive-compulsive disorder, or post-traumatic stress disorder prepregnancy may use the same medication during pregnancy unless contraindications exist (ACOG 2023; CANMAT [MacQueen 2016]; BAP [McAllister-Williams 2017]). Treatment should not be withheld or discontinued based only on pregnancy status (ACOG 2023).

SSRIs are preferred for use in pregnant patients who are treatment naive or who do not have a history of effective treatment with another medication (ACOG 2023). An SSRI other than citalopram may be preferred (ACOG 2023); however, use may be considered for pregnant patients with no prior medication history (CANMAT [MacQueen 2016]). SSRI dosing should be initiated with half the lowest recommended dose and titrated gradually over 4 to 10 days. Dose adjustments may be required as pregnancy progresses to keep symptoms in remission (ACOG 2023).

When medications are used, the lowest effective dose of a single agent is recommended. Optimize dosing prior to changing a medication or adding additional agents whenever possible. Monthly monitoring for symptom improvement with a validated screening tool during pregnancy is recommended. Manage side effects as needed (ACOG 2023).

Data collection to monitor pregnancy and infant outcomes following exposure to antidepressant medications is ongoing. Pregnant patients ≤45 years of age with a history of psychiatric illness are encouraged to enroll in the National Pregnancy Registry for Antidepressants (1-866-961-2388 or https://womensmentalhealth.org/research/pregnancyregistry/antidepressants).

Monitoring Parameters

ECG (patients at increased risk for QT-prolonging effects due to certain conditions); electrolytes (potassium and magnesium concentrations [prior to initiation and periodically during therapy in patients at increased risk for electrolyte abnormalities]); liver and renal function tests (baseline; as clinically indicated); serum sodium in at-risk populations (as clinically indicated); CBC (as clinically indicated); closely monitor patients for depression, clinical worsening, suicidality, psychosis, or unusual changes in behavior (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, mania), particularly during the initial 1 to 2 months of therapy or during periods of dosage adjustments (increases or decreases); signs/symptoms of serotonin syndrome such as mental status changes (eg, agitation, hallucinations, delirium, coma), autonomic instability (eg, tachycardia, labile BP, diaphoresis), neuromuscular changes (eg, tremor, rigidity, myoclonus), GI symptoms (eg, nausea, vomiting, diarrhea), and/or seizures.

Mechanism of Action

A racemic bicyclic phthalane derivative, citalopram selectively inhibits serotonin reuptake in the presynaptic neurons and has minimal effects on norepinephrine or dopamine. Uptake inhibition of serotonin is primarily due to the S-enantiomer of citalopram. Displays little to no affinity for serotonin, dopamine, adrenergic, histamine, GABA, or muscarinic receptor subtypes.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action:

Anxiety disorders (generalized anxiety, obsessive-compulsive, panic, and posttraumatic stress disorder): Initial effects may be observed within 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Issari 2016; Varigonda 2016; WFSBP [Bandelow 2023a]); some experts suggest up to 12 weeks of treatment may be necessary for response, particularly in patients with obsessive-compulsive disorder and posttraumatic stress disorder (BAP [Baldwin 2014]; Katzman 2014; WFSBP [Bandelow 2023a]; WFSBP [Bandelow 2023b]).

Depression: Initial effects may be observed within 1 to 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009; Taylor 2006).

Premenstrual dysphoric disorder: Initial effects may be observed within the first few days of treatment, with response at the first menstrual cycle of treatment (ISPMD [Nevatte 2013]).

Duration: 1 to 2 days.

Distribution: Vd: 12 L/kg.

Protein binding, plasma: ~80%.

Metabolism: Extensively hepatic, via CYP3A4 and 2C19 (major pathways), and 2D6 (minor pathway); metabolized to demethylcitalopram (DCT), didemethylcitalopram (DDCT), citalopram-N-oxide, and a deaminated propionic acid derivative, which are at least eight times less potent than citalopram.

Bioavailability: 80%; tablets and oral solution are bioequivalent.

Half-life elimination: 24 to 48 hours (average: 35 hours); doubled with hepatic impairment and increased by 30% (following multiple doses) to 50% (following single dose) in elderly patients (≥60 years).

Time to peak, serum: 1 to 6 hours, average within 4 hours.

Excretion: Urine (Citalopram 10% and DCT 5%).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Oral clearance decreased 17% in mild to moderate renal impairment. Limited information is available in patients with severe impairment (Joffe 1998; Spigset 2000).

Hepatic function impairment: Oral clearance decreased 37%, half-life doubled, and plasma concentrations increased in reduced hepatic function.

Older adult: Multiple dose: AUC increased 23% and half-life increased 30%. Single dose: AUC increased 30% and half-life increased 50%.

Sex: AUC in women was 1.5 to 2 times that in men in 3 studies; no difference was observed in 5 other studies.

CYP2C19 poor metabolizers: Steady state Cmax and AUC increased by 68% and 107%, respectively.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Cipram | Lopram;
  • (AR) Argentina: Apo citalopram | Citalopram northia | Citta | Humorap | Lenepal | Lopradep | Psiconor | Seropram | Zentius;
  • (AT) Austria: Citalhexal | Citalopram 1a pharma gmbh | Citalopram actavis | Citalopram arcana | Citalopram bluefish | Citalopram genericon-pharma | Citalopram hexal pharma | Citalopram interpharm | Citalopram ranbaxy | Citalopram ratiopharm | Citalopram sandoz | Citalopram torrex pharma gmbh | Citalostad | Eostar | Pram | Seropram;
  • (AU) Australia: A citalopram | Apo citalopram | Apx citalopram | Auro Citalopram | Celapram | Celica | Chem mart citalopram | Ciazil | Cipramil | Citalopram | Citalopram an | Citalopram Ga | Citalopram Generichealth | Citalopram Pfizer | Citalopram sandoz | Citalopram Winthrop | Cm citalopram | Genrx Citalopram | Noumed citalopram | Pharmacor citalopram | Talam | Talohexal | Tw citalopram;
  • (BD) Bangladesh: Arpolax | Cis-20 | Citalon | Citapram | Talopram;
  • (BE) Belgium: Cipramil | Cipramil aktuapharma | Citalomyl | Citalopram ab | Citalopram actavis | Citalopram Bexal | Citalopram eg | Citalopram eurogenerics | Citalopram Generix | Citalopram merck-generics | Citalopram ratiopharm | Citalopram sandoz | Citalopram teva generics belgium | Depresmil;
  • (BG) Bulgaria: Antidepressa | Oropram | Seropram;
  • (BR) Brazil: Alcytam | Bromidrato de citalopram | Celapram | Cipramil | Citaforin | Citagran | Citalopram | Citta | Denyl | Maxapran | Nypram | Procimax | Tensiopax | Zoxipan | Zycitapram;
  • (CH) Switzerland: Citalopram 1 A Pharma | Citalopram actavis | Citalopram Adico | Citalopram axapharm | Citalopram ecosol | Citalopram Helvepharm | Citalopram Mepha | Citalopram mepha teva | Citalopram Pfizer | Citalopram sandoz | Citalopram spirig hc | Citalopram zentiva | Claropram | Claropram spirig hc | Seropram;
  • (CL) Chile: Actipram | Cimal | Cipramil | Citalopram | Citta | Cortram | Finap | Pramcil | Prisma | Setronil | Temperax | Zebrak | Zentius;
  • (CN) China: Cipramil | Duo fu | Mai ke wei | Wang You | Xi tai le | Yi tai na | Yi te an;
  • (CO) Colombia: Civulan | Seropram | Zentius;
  • (CZ) Czech Republic: Apo Cital | Cerotor | Citalec | Citalon | Citalopram | Citalopram +Pharma | Citalopram aurovitas | Citalopram biotika | Citalopram bluefish | Citalopram orion | Citalopram ratiopharm | Citalopram teva | Citalopram top pharmex | Citalopram vitabalans | Dalsan | Pram | Seropram | Zyloram;
  • (DE) Germany: Cipramil | Citadura | Citalich | Citalo-Q | Citalogamma | Citalon | Citalopram | Citalopram 1a pharma | Citalopram abz | Citalopram actavis | Citalopram al | Citalopram amarox | Citalopram aristo | Citalopram Atid | Citalopram Awd | Citalopram Basics | Citalopram beta | Citalopram Bioeq | Citalopram bluefish | Citalopram CT | Citalopram dura | Citalopram Farmaplant | Citalopram hennig | Citalopram Heumann | Citalopram hexal | Citalopram Holsten | Citalopram Isis | Citalopram orifarm | Citalopram puren | Citalopram q pharm | Citalopram ratiopharm | Citalopram sandoz | Citalopram stada | Citalopram vitabalans | Citalopram-hormosan | Citalostad | Futuril | Sepram | Serital;
  • (DK) Denmark: Akarin | Cipramil | Citadur | Citaham | Citalopram 1a farma | Citalopram alpharma | Citalopram biochemie | Citalopram copyfarm | Citalopram hexal | Citalopram orion | Citalopram pliva | Citalopram ratiopharm;
  • (DO) Dominican Republic: Actipram | Cipramil | Citara | Citopram | Si q | Zalopram | Zentius | Zodep;
  • (EC) Ecuador: Actipram | Cimal | Humorap | Prisma | Vibel | Zentius;
  • (EE) Estonia: Cipramil | Ciral | Citalanorm | Citalec | Citalopram alpharma | Citalopram pliva | Citalopram vitabalans | Citalostad | Pram | Zyloram;
  • (EG) Egypt: Ceropram | Cipram | Cipramax | Citalo | Citalofar | Depram | Depressil | Lecital | Puracit | Ramdeep | Sedopram | Talopram;
  • (ES) Spain: Citalopram | Citalopram Acost | Citalopram actavis | Citalopram Almus | Citalopram alter | Citalopram aphar | Citalopram Apotex | Citalopram Arafarma group | Citalopram aristo | Citalopram asol | Citalopram bayvit | Citalopram Bexal | Citalopram Cinfa | Citalopram cuve | Citalopram edigen | Citalopram farmalider | Citalopram grapa | Citalopram kern | Citalopram korhispana | Citalopram Lareq | Citalopram mabo | Citalopram normon | Citalopram Pensa | Citalopram pharmagenus | Citalopram Qualigen | Citalopram ranbaxy | Citalopram Ranbaxygen | CITALOPRAM RATIO | Citalopram ratiopharm | Citalopram Rimafar | Citalopram sandoz | Citalopram stada | Citalopram sumol | Citalopram Tarbis | Citalopram teva | Citalopram vir | Citalopram Winthrop | Citalvir | Genprol | Prisdal | Relapaz | Seregra | Seropram;
  • (FI) Finland: Cipramil | Citalopram actavis | Citalopram alpharm | Citalopram arrow | Citalopram bmm pharma | Citalopram Epipharm | Citalopram generic | Citalopram hexal | Citalopram orion | Citalopram ratiopharm | Citalopram sandoz | Citalopram teva | Citalopram vitabalans | Emocal | Sepram;
  • (FR) France: Citalopram actavis | Citalopram Almus | Citalopram alter | Citalopram arrow | Citalopram Biogaran | Citalopram bluefish | Citalopram eg | Citalopram Evolugen | Citalopram g gam | Citalopram irex | Citalopram Isomed | Citalopram ivax | Citalopram merck | Citalopram Qualimed | Citalopram ratiopharm | Citalopram rpg | Citalopram sandoz | Citalopram Zydus | Seropram;
  • (GB) United Kingdom: Cipramil | Citalopram | Citalopram Almus | Citalopram arrow | Citalopram cox | Citalopram kent | Citalopram sandoz | Paxoran;
  • (GR) Greece: A depress therapy | Acelopam | Adeprenal | Alepram | Cinapen | Cipraned | Citalgert | Citaloprol | Decilop | Ecloram | Erlicon | Exenadil | Galopran | Goldamit | Kylipram | Lodeprem | Lopracil | Lopraxer | Malicon | Nevropram | Pralotam | Pramital | Prefucet | Pricital | Renevil | Ropramin | Selon | Seproc | Seropram | Seror | Siloam | Sotovon | Talopram | Taloram | Talosin | Tasonade | Unstress | Varom | Verus | Xadorek | Zanipram;
  • (HK) Hong Kong: Apo citalopram | Arpolax | Cipram | Europram | Pms Citalopram;
  • (HR) Croatia: Citalon | Starcitin;
  • (HU) Hungary: Apertia | Citagen | Citalodep | Citalopram bluefish | Citalopram orion | Citalopram pliva | Citalopram ratiopharm | Citalopram vitabalans | Citalopram zentiva | Citapram | Dalsan | Sepram | Seropram | Serotor | Zyloram;
  • (ID) Indonesia: Cipram;
  • (IE) Ireland: Bellcital | Ciprager | Cipralam | Cipramil | Ciprapine | Ciprotan | Citalopram | Citalopram niche | Citalopram teva | Citrol;
  • (IL) Israel: Cipramil | Recital;
  • (IN) India: C-pram | C-talo | Celepra | Celica | Cita | Citadep | Citalent | Citalop | Citara | Citola | Citopam | Citra | Cytop | Feliz | Lopram | Madam | Natalo | Seropram | Topdep | Ultidep | Zetalo;
  • (IS) Iceland: Cipramil;
  • (IT) Italy: Cinavol | Citalopram | Citalopram abc | Citalopram Actavis | Citalopram actavis | Citalopram Almus | Citalopram alter | Citalopram doc generici | Citalopram eg | Citalopram Pensa | Citalopram Ranbaxy | Citalopram ranbaxy | Citalopram Stg | Citepamix | Citesint | Elopram | Feliximir | Frimaind | Kaidor | Lampopram | Marpram | Percitale | Pramexyl | Return | Ricap | Seropram | Sintopram | Verisan | Vivipram;
  • (JO) Jordan: Cipram | Cipratal | Citapram | Depran | Lecital | Talopram;
  • (KE) Kenya: Cipram | Citopam | Feliz | Lopram;
  • (KR) Korea, Republic of: Cipram | Sandoz Citalopram;
  • (KW) Kuwait: Cipram | Cipratal | Lopram;
  • (LB) Lebanon: Cipram | Citadep | Citapram | Lecital | Lopram | Pms Citalopram;
  • (LT) Lithuania: Cipramil | Ciral | Citalanorm | Citalec | Citalopram | Citalopram bmm pharma | Citalopram pliva | Citalopram sandoz | Citalopram vitabalans | Citalostad | Pram | Zyloram;
  • (LU) Luxembourg: Cipramil | Citalopram eg | Citalopram hexal;
  • (LV) Latvia: Alorit | Cipramil | Ciral | Citalanorm | Citalec | Citalopram | Citalopram actavis | Citalopram pliva | Citalopram vitabalans | Citalostad | Pram | Zyloram;
  • (MX) Mexico: Anivuneo | Apopran | Cibrom | Citalopram | Citox | Lugtreran | Norecsero | Omisip | Prepram | Remicital | Seropram | Talzigort | Zinetron;
  • (MY) Malaysia: Apo citalopram | Cipram | Cital;
  • (NG) Nigeria: Lecital;
  • (NL) Netherlands: Cipramil | Citalopram | Citalopram 40 mg/ml focus | Citalopram a | Citalopram aurobindo | Citalopram bluefish | Citalopram cf | Citalopram strides;
  • (NO) Norway: Cipramil | Ciprex | Citalopram | Citalopram bmm pharma | Citalopram gea | Citalopram hexal | Citalopram orion | Citalopram sandoz | Citalopram teva | Citalopram vitabalans;
  • (NZ) New Zealand: Arrow Citalopram | Celapram | Cipramil | Citalopram | Noumed citalopram;
  • (OM) Oman: Citom;
  • (PE) Peru: Ansiodex | Cipramil | Citopam | Humorap | Hydertan | Zentius;
  • (PH) Philippines: Feliz | Lupram;
  • (PK) Pakistan: Abgenix | Allum | Alopra | Brainese | Celesta | Cheer | Cilopram | Cipram | Citalo | Citalovis | Citarid | Citatrio | Citopram | Cutapam | Dep ez | Depinor | Deprapram | Dozoprim | Eradep | Ezicit | Giggle | Glit pam | Hapicit | Iprin | Itopram | Lexapram | Lexer | Lopram | Manipram | Mitra | Nomolax | Novipram | Pram | Pramcit | Pramtec | S Pram | Stilopic | Talopram | Teknopram | Unipram | Winpram | Yalpram;
  • (PL) Poland: Aurex | Cipramil | Citabax | Cital | Citalec | Citalopram bluefish | Citalopram bmm pharma | Citalopram teva | Citalopram vitabalans | Citaratio | Citaxin | Citronil | Oropram | Pram;
  • (PR) Puerto Rico: Celexa | Citalopram | Citalopram hbr;
  • (PT) Portugal: Citalopram actavis | Citalopram aurobindo | Citalopram aurovitas | Citalopram azevedos | Citalopram Generis | Citalopram Generis Phar | Citalopram wynn | Zitolex;
  • (PY) Paraguay: Actipram | Ansiodex | Cimal | Humorap | Loxpram | Zentius;
  • (QA) Qatar: Celexa | Citalogen | Lecital | Lopram;
  • (RO) Romania: Citalopram stada | Citaloran | Linisan;
  • (RU) Russian Federation: Cipramil | Citalec | Citalift | Citalon | Citalopram | Citalorin | Citol | Humorap | Opra | Pram | Sedopram | Siozam;
  • (SA) Saudi Arabia: Apo citalopram | Cipram | Citalogen | Citalopram hexal | Citapram | Depran | Lecital | Lopra | Lopram | Pms Citalopram;
  • (SE) Sweden: Apertia | Cipramil | Citalopram | Citalopram aco | Citalopram actavis | Citalopram alpharma | Citalopram alternova | Citalopram arrow | Citalopram biochemie | Citalopram bluefish | Citalopram bmm pharma | Citalopram cnspharma | Citalopram ebb | Citalopram gea | Citalopram jubilant | Citalopram Merck NM | Citalopram Mylan | Citalopram nm pharma | Citalopram orifarm | Citalopram orion | Citalopram ratiopharm | Citalopram sandoz | Citalopram stada | Citalopram teva | Citalopram vitabalans;
  • (SG) Singapore: Cipram;
  • (SI) Slovenia: Cipramil | Citalopram | Citalopram lundbeck | Citalopram teva | Citalopram vitabalans | Oropram;
  • (SK) Slovakia: Citalec | Citalopram | Citalopram actavis | Citalopram bluefish | Citalopram orion | Citalopram pliva | Citalopram vitabalans | Desital | Ronal | Seropram | Zyloram;
  • (SR) Suriname: Apo citalopram | Citalopram actavis | Citalopram hbr | Citalopram Mylan;
  • (TH) Thailand: Cipram;
  • (TN) Tunisia: Celopram;
  • (TR) Turkey: Cipram | Citara | Citol | Citolap | Citolixin | Citrex | Eslopram | Laira | Pasilopram | Relaxol | Vodelax;
  • (TW) Taiwan: Apo citalopram | Cilopa | Cipram | Citao | Kitapram | Sitalo;
  • (UA) Ukraine: Cipramil | Cita sandoz | Citahexal | Citalam | Pram;
  • (UY) Uruguay: Citalopram Szabo | Citoprex | Psiconor | Seropram | Talpram | Temperax | Trimopan;
  • (VE) Venezuela, Bolivarian Republic of: Cimal | Citabiopram | Neuroless | Remicital | Seropram | Taloped | Trolam;
  • (VN) Viet Nam: Citalopram stella | Wazer;
  • (ZA) South Africa: Acti lift | Arrow Citalopram | Auro Citalopram | Austell citalopram | Bio citalopram | Cilift | Ciloram | Cipramil | Citalohexal | Citalopram Actor | Citalopram oethmaan biosims | Citalopram Winthrop | Depramil | Drl Citalopram | Glenmark citalopram | Simayla Citalopram | Talomil
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(8):651-660. doi:10.1016/S1474-4422(20)30207-6 [PubMed 32702334]
  3. Ailawadhi S, Sung KW, Carlson LA, Baer MR. Serotonin syndrome caused by interaction between citalopram and fentanyl. J Clin Pharm Ther. 2007;32(2):199-202. doi:10.1111/j.1365-2710.2007.00813.x [PubMed 17381671]
  4. Akbarzadeh F, Behravan G, Modaresi F, Eslamzadeh M. Citalopram-induced sleep bruxism in a breastfed infant: a case report. Front Psychiatry. 2023;14:1051346. doi:10.3389/fpsyt.2023.1051346 [PubMed 36816404]
  5. Alipour-Kivi A, Eissazade N, Shariat SV, et al. The effect of drug holidays on sexual dysfunction in men treated with selective serotonin reuptake inhibitors (SSRIs) other than fluoxetine: an 8-week open-label randomized clinical trial. BMC Psychiatry. 2024;24(1):67. doi:10.1186/s12888-024-05507-7 [PubMed 38263040]
  6. Althof SE, McMahon CG, Waldinger M, et al. An update of the International Society of Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation (PE). Sexual Med. 2014;2(2):60-90. doi:10.1002/sm2.28 [PubMed 25356302]
  7. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf. 2010;5(1):97-104. doi:10.2174/157488610789869265 [PubMed 20210726]
  8. American Academy of Child and Adolescent Psychiatry (AACAP). Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):98-113. doi:10.1016/j.jaac.2011.09.019 [PubMed 22176943]
  9. American College of Obstetricians and Gynecologists (ACOG). Treatment and management of mental health conditions during pregnancy and postpartum: ACOG clinical practice guideline No. 5. Obstet Gynecol. 2023;141(6):1262-1288. doi:10.1097/AOG.0000000000005202 [PubMed 37486661]
  10. American Psychiatric Association. Guideline watch (March 2009): Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/acutestressdisorderptsd-watch.pdf. Published March 2009a. Accessed August 2, 2018.
  11. American Psychiatric Association. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/acutestressdisorderptsd.pdf. Published November 2004. Accessed July 20, 2021.
  12. American Psychiatric Association. Practice guideline for the treatment of patients with eating disorders, 3rd edition. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/eatingdisorders.pdf. Published June 2006. Accessed August 13, 2018.
  13. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Published October 2010. Accessed March 27, 2019.
  14. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder, 2nd edition. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. Published January 2009b. Accessed March 11, 2015.
  15. American Psychological Association (APA). Clinical practice guideline for the treatment of depression across three age cohorts. https://www.apa.org/depression-guideline/guideline.pdf. Published February 16, 2019. Accessed July 26, 2021.
  16. Andersohn F, Konzen C, Bronder E, Klimpel A, Garbe E. Citalopram-induced bleeding due to severe thrombocytopenia. Psychosomatics. 2009;50(3):297-298. doi:10.1176/appi.psy.50.3.297 [PubMed 19567773]
  17. Anderson KN, Lind JN, Simeone RM, et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. JAMA Psychiatry. 2020;77(12):1246-1255. doi:10.1001/jamapsychiatry.2020.2453 [PubMed 32777011]
  18. Anderson PO. Antidepressants and breastfeeding. Breastfeed Med. 2021;16(1):5-7. doi:10.1089/bfm.2020.0350 [PubMed 33237799]
  19. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. doi:10.1002/cpt.377 [PubMed 27060684]
  20. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71(12):1565-1575. doi:10.4088/JCP.09r05786blu [PubMed 21190637]
  21. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(6):811-819. doi:10.1038/ajg.2014.82 [PubMed 24777151]
  22. Assimon MM, Brookhart MA, Flythe JE. Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis. J Am Soc Nephrol. 2019;30(4):611-623. doi:10.1681/ASN.2018101032 [PubMed 30885935]
  23. Atmaca M, Kuloglu M, Tezcan E, Semercioz A. The efficacy of citalopram in the treatment of premature ejaculation: a placebo controlled study. Int J Impot Res. 2002a;14(6):502-505. doi:10.1038/sj.ijir.3900918 [PubMed 12494286]
  24. Atmaca M, Kuloglu M, Tezcan E, Unal A. Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002b;17(8):401-405. [PubMed 12457375]
  25. Auerbach AD, Vittinghoff E, Maselli J, Pekow PS, Young JQ, Lindenauer PK. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. JAMA Intern Med. 2013;173(12):1075-1081. doi:10.1001/jamainternmed.2013.714 [PubMed 23699725]
  26. Bai AD, McKenna S, Wise H, Loeb M, Gill SS. Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants. JAMA Netw Open. 2022;5(12):e2247426. doi:10.1001/jamanetworkopen.2022.47426 [PubMed 36534400]
  27. Bala A, Nguyen HMT, Hellstrom WJG. Post-SSRI sexual dysfunction: a literature review. Sex Med Rev. 2018;6(1):29-34. doi:10.1016/j.sxmr.2017.07.002 [PubMed 28778697]
  28. Baldessarini RJ, Faedda GL, Offidani E, et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. J Affect Disord. 2013;148(1):129-135. doi:10.1016/j.jad.2012.10.033 [PubMed 23219059]
  29. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-439. doi:10.1177/0269881114525674 [PubMed 24713617]
  30. Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. World J Biol Psychiatry. 2023a;24(2):79-117. doi:10.1080/15622975.2022.2086295 [PubMed 35900161]
  31. Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part II: OCD and PTSD. World J Biol Psychiatry. 2023b;24(2):118-134. doi:10.1080/15622975.2022.2086296 [PubMed 35900217]
  32. Barak Y, Kimhi R, Weizman R. Is selectivity for serotonin uptake associated with a reduced emergence of manic episodes in depressed patients?. Int Clin Psychopharmacol. 2000;15(1):53-56. doi:10.1097/00004850-200015010-00009 [PubMed 108362889]
  33. Barbuti M, Pacchiarotti I, Vieta E, et al. Antidepressant-induced hypomania/mania in patients with major depression: Evidence from the BRIDGE-II-MIX study. J Affect Disord. 2017;219:187-192. doi:10.1016/j.jad.2017.05.035 [PubMed 28558366]
  34. Barclay TS, Lee AJ. Citalopram-associated SIADH. Ann Pharmacother. 2002;36(10):1558-1563. doi:10.1345/aph.1C071 [PubMed 12243606]
  35. Bartlett D. Drug-Induced Serotonin Syndrome. Crit Care Nurse. 2017;37(1):49-54. doi:10.4037/ccn2017169 [PubMed 28148614]
  36. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol. 2010;28(20):3278-3283. doi: 10.1200/JCO.2009.26.6379. [PubMed 20498389]
  37. Bauer M, Pfennig A, Severus E, et al; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334-385. [PubMed 23879318]
  38. Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry. 2002;3(2):69-86. [PubMed 12479080]
  39. Bauer M, Severus E, Köhler S, et al; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015;16(2):76-95. doi: 10.3109/15622975.2014.1001786. [PubMed 25677972]
  40. Baumgartner JL, Emslie GJ, Crismon ML. Citalopram in children and adolescents with depression or anxiety. Ann Pharmacother. 2002;36(11):1692-1697. doi:10.1345/aph.1C078 [PubMed 12398561]
  41. Beach SR, Celano CM, Sugrue AM, et al. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018;59(2):105-122. doi:10.1016/j.psym.2017.10.009 [PubMed 29275963]
  42. Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014;75(5):e441-e449. doi:10.4088/JCP.13r08672 [PubMed 24922496]
  43. Beckwith AR. The precipitation of mania by citalopram in a patient with interferon-induced depression. Psychosomatics. 2008;49(4):362-363. doi:10.1176/appi.psy.49.4.362-a [PubMed 18621943]
  44. Benazzi F. Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord. 1997;46(1):73-77. doi:10.1016/s0165-0327(97)00082-7 [PubMed 9387089]
  45. Berk M, Acton M. Citalopram-associated clitoral priapism: a case series. Int Clin Psychopharmacol. 1997;12(2):121-122. doi:10.1097/00004850-199703000-00008 [PubMed 9219048]
  46. Berle JO, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev. 2011;7(1):28-34. [PubMed 22299006]
  47. Bernard L, Stern R, Lew D, et al, “Serotonin Syndrome After Concomitant Treatment With Linezolid and Citalopram,” Clin Infect Dis, 2003, 36(9):1197. [PubMed 12715317]
  48. Bertolín S, Alonso P, Segalàs C, et al. First manic/hypomanic episode in obsessive-compulsive disorder patients treated with antidepressants: a systematic review. J Psychiatr Res. 2021;137:319-327. doi:10.1016/j.jpsychires.2021.02.060 [PubMed 33744511]
  49. Biffi A, Cantarutti A, Rea F, Locatelli A, Zanini R, Corrao G. Use of antidepressants during pregnancy and neonatal outcomes: an umbrella review of meta-analyses of observational studies. J Psychiatr Res. 2020;124:99-108. doi:10.1016/j.jpsychires.2020.02.023 [PubMed 32135392]
  50. Bixby AL, VandenBerg A, Bostwick JR. Clinical Management of Bleeding Risk With Antidepressants. Ann Pharmacother. 2019;53(2):186-194. doi:10.1177/1060028018794005 [PubMed 30081645]
  51. Blank S, Lenze EJ, Mulsant BH, et al. Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment. J Clin Psychiatry. 2006;67(3):468-472. [PubMed 16649835]
  52. Bobo WV. The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update. Mayo Clin Proc. 2017;92(10):1532-1551. doi:10.1016/j.mayocp.2017.06.022 [PubMed 28888714]
  53. Bourgeois JA, Babine SE, Bahadur N. A case of SIADH and hyponatremia associated with citalopram. Psychosomatics. 2002;43(3):241-242. doi:10.1176/appi.psy.43.3.241 [PubMed 12075041]
  54. Boyer EW, Shannon M. The serotonin syndrome [published correction appears in N Engl J Med. 2007 Jun 7;356(23):2437] [published correction appears in N Engl J Med. 2009 Oct 22;361(17):1714]. N Engl J Med. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867 [PubMed 15784664]
  55. Butterfield JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, Lodise TP. Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data. J Antimicrob Chemother. 2012;67(2):494-502. doi:10.1093/jac/dkr467 [PubMed 22139199]
  56. Calandra C, Gulino V, Inserra L, Giuffrida A. The use of citalopram in an integrated approach to the treatment of eating disorders: an open study. Eat Weight Disord. 1999;4(4):207-210. [PubMed 10728184]
  57. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: A critical review of the literature. Psychother Psychosom. 2016;85(5):270-288. doi:10.1159/000447034 [PubMed 27508501]
  58. Casper RF, Yonkers KA. Treatment of premenstrual syndrome and premenstrual dysphoric disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 8, 2023.
  59. Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288. Published 2013 Jan 29. doi:10.1136/bmj.f288 [PubMed 23360890]
  60. Celexa capsules (citalopram) [prescribing information]. Morristown, NJ: Almatica Pharma LLC; August 2023.
  61. Celexa tablets (citalopram) [prescribing information]. North Chicago, IL: AbbVie inc; October 2023.
  62. Celexa tablets (citalopram) [product monograph]. Saint-Laurent, Quebec, Canada: Lundbeck Canada Inc; February 2024.
  63. Ceylan ME, Maner F. Long-term use of fluoxetine and multiple skeleton fractures. Eur J Clin Pharmacol. 2010;66(12):1279. doi:10.1007/s00228-010-0880-8 [PubMed 20703452]
  64. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579-587. [PubMed 16467545]
  65. Chen HY, Lin CL, Lai SW, Kao CH. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. J Clin Psychiatry. 2016;77(6):e692-e696. doi:10.4088/JCP.15m10038 [PubMed 27135704]
  66. Cheung AH, Kozloff N, Sacks D. Pediatric depression: an evidence-based update on treatment interventions. Curr Psychiatry Rep. 2013;15(8):381. doi:10.1007/s11920-013-0381-4 [PubMed 23881712]
  67. Cheung AH, Zuckerbrot RA, Jensen PS, Laraque D, Stein REK; GLAD-PC Steering Group. Guidelines for adolescent depression in primary care (GLAD-PC): Part II. Treatment and ongoing management. Pediatrics. 2018;141(3):e20174082. doi:10.1542/peds.2017-4082 [PubMed 29483201]
  68. Chou PH, Chu CS, Chen YH, et al. Antidepressants and risk of cataract development: A population-based, nested case-control study. J Affect Disord. 2017;215:237-244. doi:10.1016/j.jad.2017.03.044 [PubMed 28342338]
  69. Citalopram oral solution [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; June 2021.
  70. Clayton AH, Gommoll C, Chen D, Nunez R, Mathews M. Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial. Int Clin Psychopharmacol. 2015;30(4):216-223. doi:10.1097/YIC.0000000000000075 [PubMed 26039688]
  71. Cooke MJ, Waring WS. Citalopram and cardiac toxicity. Eur J Clin Pharmacol. 2013;69(4):755-760. doi:10.1007/s00228-012-1408-1 [PubMed 22996077]
  72. Coskuner ER, Culha MG, Ozkan B, Kaleagasi EO. Post-SSRI sexual dysfunction: preclinical to clinical. Is it fact or fiction?. Sex Med Rev. 2018;6(2):217-223. doi:10.1016/j.sxmr.2017.11.004 [PubMed 29463440]
  73. Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. Curr Neuropharmacol. 2008;6(4):293-310. doi:10.2174/157015908787386104 [PubMed 19587851]
  74. Coughlin CG, Jakubovski E, Bloch MH. Time course and predictors of suicidal ideation during citalopram treatment in the STAR*D trial. J Clin Psychiatry. 2016;77(10):e1262-e1269. doi:10.4088/JCP.15m10075 [PubMed 27631142]
  75. Craske M, Bystritsky A. Generalized anxiety disorder in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 8, 2023.
  76. Crépeau-Gendron G, Brown HK, Shorey C, et al. Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting. J Affect Disord. 2019;250:341-345. doi:10.1016/j.jad.2019.02.060 [PubMed 30877856]
  77. Crocco EA, Jaramillo S, Cruz-Ortiz C, Camfield K. Pharmacological management of anxiety disorders in the elderly. Curr Treat Options Psychiatry. 2017;4(1):33-46.
  78. Crone C, Fochtmann LJ, Attia E, et al; Guideline Writing Group. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders. 4th ed. American Psychiatric Association; 2023. doi:10.1176/appi.books.9780890424865
  79. Croos R, Thirumalai S, Hassan S, Davis Jda R. Citalopram associated with acute angle-closure glaucoma: case report. BMC Ophthalmol. 2005;5:23. Published 2005 Oct 4. doi:10.1186/1471-2415-5-23 [PubMed 16202173]
  80. Crow SJ. Bulimia nervosa in adults: pharmacotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 23, 2021.
  81. Csoka AB, Shipko S. Persistent sexual side effects after SSRI discontinuation. Psychother Psychosom. 2006;75(3):187-188. doi:10.1159/000091777 [PubMed 16636635]
  82. Csoka AB, Bahrick A, Mehtonen OP. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors [published correction appears in J Sex Med. 2008 Dec;5(12):2977. Csoka, A [corrected to Csoka, AB]]. J Sex Med. 2008;5(1):227-233. doi:10.1111/j.1743-6109.2007.00630.x [PubMed 18173768]
  83. CTP 30 (citalopram hydrobromide) [product monograph]. Mississauga, Ontario, Canada: Sumitomo Pharma Canada Inc; June 2024.
  84. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2009;7(12):1314-1321. doi:10.1016/j.cgh.2009.08.019 [PubMed 19716436]
  85. de Gregorio C, Morabito G, Cerrito M, Dattilo G, Oreto G. Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease. Int J Cardiol. 2011;148(2):226-228. doi:10.1016/j.ijcard.2009.05.060 [PubMed 19540606]
  86. De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. Psychosomatics. 2014;55(6):536-547. doi:10.1016/j.psym.2014.01.010 [PubMed 25262043]
  87. Dennis M, Forbes J, Graham C, et al. Fluoxetine to improve functional outcomes in patients after acute stroke: the FOCUS RCT. Health Technol Assess. 2020;24(22):1-94. doi:10.3310/hta24220 [PubMed 32452356]
  88. Depression in children and young people: identification and management. London: National Institute for Health and Care Excellence (NICE) (UK); June 25, 2019. [PubMed 31577402]
  89. Dietrichs ES, Smith GL. Prediction of ventricular arrhythmias by QRS/QTc - ratio in citalopram or escitalopram intoxication. Front Med (Lausanne). 2022;9:866454. doi:10.3389/fmed.2022.866454 [PubMed 35372426]
  90. Dodd S, Mitchell PB, Bauer M, et al. Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: an international consensus statement. World J Biol Psychiatry. 2018;19(5):330-348. doi:10.1080/15622975.2017.1379609 [PubMed 28984491]
  91. Dopheide JA. Recognizing and treating depression in children and adolescents. Am J Health Syst Pharm. 2006;63(3):233-243. [PubMed 16434782]
  92. Douros A, Ades M, Renoux C. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: A systematic review. CNS Drugs. 2018;32(4):321-334. doi:10.1007/s40263-018-0507-7 [PubMed 29536379]
  93. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109 [PubMed 12925718]
  94. Durmaz O, Çelik S. Vaginal bleeding associated with antidepressants. Int J Gynaecol Obstet. 2015;130(3):284. doi:10.1016/j.ijgo.2015.03.024 [PubMed 25983210]
  95. EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(8):661-669. doi:10.1016/S1474-4422(20)30219-2 [PubMed 32702335]
  96. Elsnhory A, Hasan MT, Hagrass AI, et al. Recovery in stroke patients treated with fluoxetine versus placebo: a pooled analysis of 7,165 patients. Neurologist. 2023;28(2):104-116. doi:10.1097/NRL.0000000000000451 [PubMed 35777860]
  97. English BA, Jewell M, Jewell G, Ambrose S, Davis LL. Treatment of chronic posttraumatic stress disorder in combat veterans with citalopram: an open trial. J Clin Psychopharmacol. 2006;26(1):84-88. doi:10.1097/01.jcp.0000195043.39853.bc [PubMed 16415713]
  98. Erie JC, Brue SM, Chamberlain AM, Hodge DO. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. Am J Ophthalmol. 2014;158(1):192-197.e1. doi:10.1016/j.ajo.2014.03.006 [PubMed 24631758]
  99. Etminan M, Mikelberg FS, Brophy JM. Selective serotonin reuptake inhibitors and the risk of cataracts: a nested case-control study. Ophthalmology. 2010;117(6):1251-1255. doi:10.1016/j.ophtha.2009.11.042 [PubMed 20207418]
  100. Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, FCCP; Jeong Park, PharmD, MS, BCPS, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.
  101. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  102. Farmand S, Lindh JD, Calissendorff J, et al. Differences in associations of antidepressants and hospitalization due to hyponatremia. Am J Med. 2018;131(1):56-63. doi:10.1016/j.amjmed.2017.07.025 [PubMed 28803926]
  103. Farmand S, Lindh JD, Calissendorff J, et al. Corrigendum to "Differences in associations of antidepressants and hospitalization due to hyponatremia" AmJMed, 131(01);56-63. Am J Med. 2021;134(4):554. doi:10.1016/j.amjmed.2020.12.003 [PubMed 33485536]
  104. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. Psychother Psychosom. 2015;84(2):72-81. doi:10.1159/000370338 [PubMed 25721705]
  105. Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. Am Fam Physician. 2009;80(3):239-245. [PubMed 19621834]
  106. Fitton CA, Steiner MFC, Aucott L, et al. In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. Acta Psychiatr Scand. 2020;141(1):21-33. doi:10.1111/acps.13120 [PubMed 31648376]
  107. Flores G, Perez-Patrigeon S, Cobos-Ayala C, Vergara J. Severe symptomatic hyponatremia during citalopram therapy--a case report. BMC Nephrol. 2004;5:2. doi:10.1186/1471-2369-5-2 [PubMed 14728721]
  108. Freeman EW, Jabara S, Sondheimer SJ, Auletto R. Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. J Womens Health Gend Based Med. 2002;11(5):459-464. doi: 10.1089/15246090260137635. [PubMed 12165163]
  109. Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med. 2007;356(23):2343-2346. doi:10.1056/NEJMp078015 [PubMed 17485726]
  110. Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013;47(10):1330-1341. doi:10.1177/1060028013501994 [PubMed 24259697]
  111. Furmark T, Appel L, Michelgård A, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry. 2005;58(2):132-142. doi: 10.1016/j.biopsych.2005.03.029. [PubMed 16038684]
  112. Gaanderse M, Kliffen J, Linssen W. Citalopram-induced dyskinesia of the tongue: a video presentation. BMJ Case Rep. 2016;2016:bcr2016216126. doi:10.1136/bcr-2016-216126 [PubMed 28011457]
  113. Gandhi S, Shariff SZ, Al-Jaishi A, et al. Second-generation antidepressants and hyponatremia risk: A population-based cohort study of older adults. Am J Kidney Dis. 2017;69(1):87-96. doi:10.1053/j.ajkd.2016.08.020 [PubMed 27773479]
  114. Gao SY, Wu QJ, Sun C, et al. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. BMC Med. 2018;16(1):205. doi:10.1186/s12916-018-1193-5 [PubMed 30415641]
  115. Gill N, Bayes A, Parker G. A review of antidepressant-associated hypomania in those diagnosed with unipolar depression-risk factors, conceptual models, and management. Curr Psychiatry Rep. 2020;22(4):20. doi:10.1007/s11920-020-01143-6 [PubMed 32215771]
  116. Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002;36(10):1577-1589. doi:10.1345/aph.1A195 [PubMed 12243609]
  117. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001;24(3):183-197. [PubMed 11347722]
  118. Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci. 2007;9(1):47-59. [PubMed 17506225]
  119. Hamad GG, Helsel JC, Perel JM, et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry. 2012;169(3):256-263. doi:10.1176/appi.ajp.2011.11050719 [PubMed 22407114]
  120. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332-339. doi:10.1001/archpsyc.63.3.332 [PubMed 16520440]
  121. Hankey GJ, Hackett ML, Almeida OP, et al. Twelve-month outcomes of the AFFINITY trial of fluoxetine for functional recovery after acute stroke: AFFINITY trial steering committee on behalf of the AFFINITY trial collaboration. Stroke. 2021;52(8):2502-2509. doi:10.1161/STROKEAHA.120.033070 [PubMed 34015940]
  122. Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28(10):887-920. doi:10.1007/s40263-014-0196-9 [PubMed 25168784]
  123. Hathaway EE, Walkup JT, Strawn JR. Antidepressant treatment duration in pediatric depressive and anxiety disorders: How long is long enough? Curr Probl Pediatr Adolesc Health Care. 2018;48(2):31-39. [PubMed 29337001]
  124. Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther. 2002;72(2):184-91. [PubMed 12189365]
  125. Heller HM, Ravelli ACJ, Bruning AHL, et al. Increased postpartum haemorrhage, the possible relation with serotonergic and other psychopharmacological drugs: a matched cohort study. BMC Pregnancy Childbirth. 2017;17(1):166. doi:10.1186/s12884-017-1334-4 [PubMed 28577352]
  126. Hetrick SE, McKenzie JE, Bailey AP, et al. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev. 2021;5(5):CD013674. doi:10.1002/14651858.CD013674.pub2 [PubMed 34029378]
  127. Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2012;11:CD004851. doi:10.1002/14651858.CD004851.pub3 [PubMed 23152227]
  128. Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthc Patient Saf. 2010;2:141-150. doi:10.2147/DHPS.S7634 [PubMed 21701626]
  129. Himmerich H, Lewis YD, Conti C, et al; WFSBP Task Force on Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. Published online April 24, 2023. World J Biol Psychiatry. doi:10.1080/15622975.2023.2179663 [PubMed 37350265]
  130. Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 26, 2023.
  131. Hirsch M, Birnbaum RJ. Selective serotonin reuptake inhibitors: pharmacology, administration, and side effects. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 1, 2024.
  132. Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 8, 2021.
  133. Hutton LMJ, Cave AJ, St-Jean R, Banh HL. Should we be worried about QTc prolongation using citalopram? A review. J Pharm Pract. 2017;30(3):353-358. doi:10.1177/0897190015624862 [PubMed 26763342]
  134. Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. J Clin Psychiatry. 2016;77(5):e605-e611. doi:10.4088/JCP.14r09758 [PubMed 27249090]
  135. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. [PubMed 10891521]
  136. Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother. 2006;40(9):1618-1622. doi:10.1345/aph.1G293 [PubMed 16896026]
  137. Jeong BO, Kim SW, Kim SY, Kim JM, Shin IS, Yoon JS. Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery. Psychosomatics. 2014;55(3):213-220. doi:10.1016/j.psym.2013.08.011 [PubMed 24314591]
  138. Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRI antidepressants is a challenge: Management tips. Am J Psychiatry. 2018;175(12):1176-1184. doi:10.1176/appi.ajp.2018.18060692 [PubMed 30501420]
  139. Jiang HY, Xu LL, Li YC, Deng M, Peng CT, Ruan B. Antidepressant use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis. J Psychiatr Res. 2016;83:160-167. doi:10.1016/j.jpsychires.2016.09.001 [PubMed 27637098]
  140. Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. Ment Health Clin. 2016;6(4):191-196. doi:10.9740/mhc.2016.07.191 [PubMed 29955469]
  141. Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jørgensen T, Sidhu J. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol. 1998;54(3):237-242. doi:10.1007/s002280050452 [PubMed 9681666]
  142. Johnson CF, Maxwell M, Williams B, Dougall N, MacGillivray S. Dose-response effects of selective serotonin reuptake inhibitor monotherapy for the treatment of depression: systematic review of reviews and meta-narrative synthesis. BMJ Med. 2022;1(1):e000017. doi:10.1136/bmjmed-2021-000017 [PubMed 36936596]
  143. Jones JS, Kimata R, Almeida OP, Hankey GJ. Risk of fractures in stroke patients treated with a selective serotonin reuptake inhibitor: a systematic review and meta-analysis. Stroke. 2021;52(9):2802-2808. doi:10.1161/STROKEAHA.120.032973 [PubMed 34167325]
  144. Kalay AE, Demir B, Haberal A, Kalay M, Kandemir O. Efficacy of citalopram on climacteric symptoms. Menopause. 2007;14(2):223-229. [PubMed 17224858]
  145. Karkow DC, Kauer JF, Ernst EJ. Incidence of serotonin syndrome with combined use of linezolid and serotonin reuptake inhibitors compared with linezolid monotherapy. J Clin Psychopharmacol. 2017;37(5):518-523. doi:10.1097/JCP.0000000000000751 [PubMed 28796019]
  146. Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1 [PubMed 25081580]
  147. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160(4):790-792. doi:10.1176/appi.ajp.160.4.790 [PubMed 12668373]
  148. Khanassov V, Hu J, Reeves D, van Marwijk H. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: A systematic review and meta-analysis. Int J Geriatr Psychiatry. 2018;33(12):1688-1708. doi:10.1002/gps.4974 [PubMed 30247774]
  149. Khera M, Cunningham GR. Treatment of male sexual dysfunction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 13, 2020.
  150. Khouri C, Blaise S, Carpentier P, Villier C, Cracowski JL, Roustit M. Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol. 2016;82(1):6-16. doi:10.1111/bcp.12912 [PubMed 26949933]
  151. Kirkham J, Seitz D. Evidence of ocular side effects of SSRIs and new warnings. Evid Based Ment Health. 2017;20(1):27. doi:10.1136/eb-2016-102528 [PubMed 27993931]
  152. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB; American Psychiatric Association. Practice guidelines for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007;164(7)(suppl):5-53. [PubMed 17849776]
  153. Kufel WD, Parsels KA, Blaine BE, Steele JM, Seabury RW, Asiago-Reddy EA. Real-world evaluation of linezolid-associated serotonin toxicity with and without concurrent serotonergic agents. Int J Antimicrob Agents. 2023;62(1):106843. doi:10.1016/j.ijantimicag.2023.106843 [PubMed 37160238]
  154. Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ. 2011;183(16):1835-1843. doi:10.1503/cmaj.100912 [PubMed 21948719]
  155. Lake MB, Birmaher B, Wassick S, et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol. 2000;10(1):35-38. [PubMed 10755580 ]
  156. Lam RW. Antidepressants and QTc prolongation. J Psychiatry Neurosci. 2013;38(2):E5-E6. doi:10.1503/jpn.120256 [PubMed 23422053]
  157. Lanza di Scalea T, Pearlstein T. Premenstrual dysphoric disorder. Med Clin North Am. 2019;103(4):613-628. doi:10.1016/j.mcna.2019.02.007 [PubMed 31078196]
  158. Lanza di Scalea T, Wisner KL. Antidepressant medication use during breastfeeding. Clin Obstet Gynecol. 2009;52(3):483-497. doi:10.1097/GRF.0b013e3181b52bd6 [PubMed 19661763]
  159. Lebin LG, Novick AM. Selective serotonin reuptake inhibitors (SSRIs) in pregnancy: an updated review on risks to mother, fetus, and child. Curr Psychiatry Rep. 2022;24(11):687-695. doi:10.1007/s11920-022-01372-x [PubMed 36181572]
  160. Legg LA, Rudberg AS, Hua X, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2021;11(11):CD009286. doi:10.1002/14651858.CD009286.pub4 [PubMed 34780067]
  161. Leinonen E, Lepola U, Koponen H, Turtonen J, Wade A, Lehto H. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci. 2000;25(1):24-32. [PubMed 10721681]
  162. Lenze EJ, Mulsant BH, Shear MK, et al. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry. 2005;162(1):146-150. [PubMed 15625213]
  163. Leombruni P, Amianto F, Delsedime N, Gramaglia C, Abbate-Daga G, Fassino S. Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: a single-blind randomized controlled trial. Adv Ther. 2006;23(3):481-494. [PubMed 16912031]
  164. Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. Am J Psychiatry. 2007;164(12):1786-1789. doi:10.1176/appi.ajp.2007.07050775 [PubMed 18056231]
  165. Leth-Møller KB, Hansen AH, Torstensson M, et al. Antidepressants and the risk of hyponatremia: a Danish register-based population study. BMJ Open. 2016;6(5):e011200. doi:10.1136/bmjopen-2016-011200 [PubMed 27194321]
  166. Letmaier M, Painold A, Holl AK, et al. Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. Int J Neuropsychopharmacol. 2012;15(6):739-748. doi:10.1017/S1461145711001192 [PubMed 21777511]
  167. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160(2):173-176. [PubMed 16461873]
  168. Lewis JD, Strom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiol Drug Saf. 2008;17(4):328-335. doi:10.1002/pds.1546 [PubMed 18188866]
  169. Li Y, Chen C, Chen Q, et al. Effects of selective serotonin reuptake inhibitors (SSRIs) on suicide: a network meta-analysis of double-blind randomized trials. Psychiatry Res. 2024;336:115917. doi:10.1016/j.psychres.2024.115917 [PubMed 38663222]
  170. Lien YH. Antidepressants and hyponatremia. Am J Med. 2018;131(1):7-8. doi:10.1016/j.amjmed.2017.09.002 [PubMed 28923523]
  171. Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports [published correction appears in Can Med Assoc J 1996;155(8):1043]. CMAJ. 1996;155(5):519-527. [PubMed 8804257]
  172. Liu H, Zhang M, Huang M, et al. Comparative efficacy and safety of drug treatment for premature ejaculation: A systemic review and Bayesian network meta-analysis. Andrologia. 2020;52(11):e13806. doi:10.1111/and.13806 [PubMed 32892379]
  173. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;27(1):31-40. doi:10.1111/j.1365-2036.2007.03541.x [PubMed 17919277]
  174. MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 6. Special populations: youth, women, and the elderly. Can J Psychiatry. 2016;61(9):588-603. doi:10.1177/0706743716659276 [PubMed 27486149]
  175. Mahlberg R, Kunz D, Sasse J, et al. Serotonin syndrome with tramadol and citalopram. Am J Psychiatry. 2004;161(6):1129. [PubMed 15169709]
  176. Mannesse CK, Jansen PA, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. Maturitas. 2013;76(4):357-363. doi:10.1016/j.maturitas.2013.08.010 [PubMed 24094459]
  177. Marano CM, Workman CI, Lyman CH, Munro CA, Kraut MA, Smith GS. Structural imaging in late-life depression: association with mood and cognitive responses to antidepressant treatment. Am J Geriatr Psychiatry. 2015;23(1):4-12. doi:10.1016/j.jagp.2013.10.001 [PubMed 24238925]
  178. Marshall AM, Nommsen-Rivers LA, Hernandez LL, et al. Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution. J Clin Endocrinol Metab. 2010;95(2):837-846. doi:10.1210/jc.2009-1575 [PubMed 19965920]
  179. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004;158(8):773-780. doi:10.1001/archpedi.158.8.773 [PubMed 15289250]
  180. Masarwa R, Bar-Oz B, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. Am J Obstet Gynecol. 2019;220(1):57.e1-57.e13. doi:10.1016/j.ajog.2018.08.030 [PubMed 30170040]
  181. Masi G. Controversies in the pharmacotherapy of adolescent depression. Curr Pharm Des. 2022;28(24):1975-1984. doi:10.2174/1381612828666220526150153 [PubMed 35619257]
  182. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000;79(4):201-209. doi:10.1097/00005792-200007000-00001 [PubMed 10941349]
  183. Massaoutis P, Goh D, Foster PJ. Bilateral symptomatic angle closure associated with a regular dose of citalopram, an SSRI antidepressant. Br J Ophthalmol. 2007;91(8):1086-1087. doi:10.1136/bjo.2006.107185 [PubMed 17638821]
  184. Mauri MC, Fiorentini A, Paletta S, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. Clin Pharmacokinet. 2014;53(12):1069-1081. doi:10.1007/s40262-014-0187-5 [PubMed 25248846]
  185. McAllister-Williams RH, Baldwin DS, Cantwell R, et al; endorsed by the British Association for Psychopharmacology. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol. 2017;31(5):519-552. doi:10.1177/0269881117699361 [PubMed 28440103]
  186. McElroy SL, Hudson JI, Malhotra S, Welge JA, Nelson EB, Keck PE Jr. Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. J Clin Psychiatry. 2003;64(7):807-813. doi:10.4088/jcp.v64n0711 [PubMed 12934982]
  187. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62 Suppl 3:10-21. [PubMed 11229449]
  188. Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001;16(2):75-86. [PubMed 11236072]
  189. Moosavi SM, Ahmadi M, Monajemi MB. Acute dystonia due to citalopram treatment: a case series. Glob J Health Sci. 2014;6(6):295-299. doi:10.5539/gjhs.v6n6p295 [PubMed 25363102]
  190. Movig KL, Janssen MW, de Waal Malefijt J, Kabel PJ, Leufkens HG, Egberts AC. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern Med. 2003;163(19):2354-2358. doi:10.1001/archinte.163.19.2354 [PubMed 14581256]
  191. Mukaddes NM, Abali O, and Kaynak N. Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary report. Psychiatry Clin Neurosci. 2003;57(4):405-408. [PubMed 12839522]
  192. Mullen S. Major depressive disorder in children and adolescents. Ment Health Clin. 2018;8(6):275-283. doi:10.9740/mhc.2018.11.275 [PubMed 30397569]
  193. Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Aliment Pharmacol Ther. 2014;40(8):880-892. doi:10.1111/apt.12925 [PubMed 25175904]
  194. Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012;27(10):3736-3745. doi:10.1093/ndt/gfs295 [PubMed 22859791]
  195. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007;27(8):1189-1197. doi:10.1592/phco.27.8.1189 [PubMed 17655517]
  196. National Collaborating Centre for Mental Health (NCCMH). Depression: The treatment and management of depression in adults (updated edition). National Institute for Health & Clinical Excellence (NICE). 2010. [PubMed 22132433]
  197. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59(4):577-585. [PubMed 21453380]
  198. Nevatte T, O'Brien PM, Bäckström T, et al; Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health. 2013;16(4):279-291. doi:10.1007/s00737-013-0346-y [PubMed 23624686]
  199. Ng QX, Venkatanarayanan N, Ho CYX, Sim WS, Lim DY, Yeo WS. Selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn: an update meta-analysis. J Womens Health (Larchmt). 2019;28(3):331-338. doi:10.1089/jwh.2018.7319 [PubMed 30407100]
  200. North American Menopause Society 2023 Nonhormone Therapy Position Statement Advisory Panel. The 2023 nonhormone therapy position statement of the North American Menopause Society. Menopause. 2023;30(6):573-590. doi:10.1097/GME.0000000000002200 [PubMed 37252752]
  201. O'Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-632. doi:10.1007/s41999-023-00777-y [PubMed 37256475]
  202. Odeh M, Beny A, Oliven A. Severe symptomatic hyponatremia during citalopram therapy. Am J Med Sci. 2001;321(2):159-160. doi:10.1097/00000441-200102000-00009 [PubMed 11217819]
  203. Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. J Pharm Pract. 2013;26(4):389-396. doi:10.1177/0897190012467210 [PubMed 23459282]
  204. Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol. 2008;66(1):76-81. doi:10.1111/j.1365-2125.2008.03154.x [PubMed 18460039]
  205. Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systematic review. Hum Psychopharmacol. 2015;30(1):4-20. doi:10.1002/hup.2451 [PubMed 25572308]
  206. Padda J, Khalid K, Hitawala G, et al. Depression and its effect on the menstrual cycle. Cureus. 2021;13(7):e16532. doi:10.7759/cureus.16532 [PubMed 34430141]
  207. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76 [PubMed 16415707]
  208. Park SH, Ishino R. Liver injury associated with antidepressants. Curr Drug Saf. 2013;8(3):207-223. doi:10.2174/1574886311308030011 [PubMed 23914755]
  209. Pass SE, Simpson RW. Discontinuation and reinstitution of medications during the perioperative period. Am J Health Syst Pharm. 2004;61(9):899-912. [PubMed 15156966]
  210. Patel R, Reiss P, Shetty H, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. BMJ Open. 2015;5(12):e008341. doi:10.1136/bmjopen-2015-008341 [PubMed 26667012]
  211. Paulzen M, Goecke TW, Stingl JC, et al. Pregnancy exposure to citalopram - Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79(Pt B):213-219. doi:10.1016/j.pnpbp.2017.06.030 [PubMed 28663113]
  212. Peacock LE, Wright F. Serotonin syndrome secondary to tramadol and citalopram. Age Ageing. 2011;40(4):528. doi:10.1093/ageing/afr017 [PubMed 21414947]
  213. Pedersen AG. Citalopram and suicidality in adult major depression and anxiety disorders. Nord J Psychiatry. 2006;60(5):392-399. doi:10.1080/08039480600937561 [PubMed 17038305]
  214. Peiró AM, Margarit C, Torra M. Citalopram-induced Raynaud's phenomenon. Rheumatol Int. 2007;27(6):599-601. [PubMed 17103176]
  215. Perna G, Bertani A, Caldirola D, Smeraldi E, Bellodi L. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2001;34(3):85-90. [PubMed 11434404]
  216. Phillips KA. Obsessive-compulsive disorder in adults: treatment overview. Connor RF, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed April 22, 2025.
  217. Pogliani L, Baldelli S, Cattaneo D, et al. Selective serotonin reuptake inhibitors' passage into human milk of lactating women. J Matern Fetal Neonatal Med. 2019;32(18):3020-3025. doi:10.1080/14767058.2018.1455180 [PubMed 29557689]
  218. Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007;15(11):942-952. doi:10.1097/JGP.0b013e3180cc1ff5 [PubMed 17846102]
  219. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159(3):460-465. doi:10.1176/appi.ajp.159.3.460 [PubMed 11870012]
  220. Porsteinsson AP, Drye LT, Pollock BG, et al; CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682-691. doi:10.1001/jama.2014.93 [PubMed 24549548]
  221. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201 [PubMed 15704999]
  222. Pravin D, Srinath S, Girimaji S, Seshadri SP. Citalopram and mania. J Am Acad Child Adolesc Psychiatry. 2004;43(7):791. doi:10.1097/01.chi.0000128831.13997.e3 [PubMed 15213579]
  223. Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos Int. 2013;24(1):121-137. [PubMed 22638709]
  224. Rampono J, Kristensen JH, Hackett LP, Paech M, Kohan R, Ilett KF. Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. Br J Clin Pharmacol. 2000;50(3):263-268. [PubMed 10971311]
  225. Ravindran LN, Woods SA, Steiner M, Ravindran AV. Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series. Arch Womens Ment Health. 2007;10(3):125-127. doi:10.1007/s00737-007-0181-0 [PubMed 17431739]
  226. Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. CNS Neurosci Ther. 2010;16(4):227-234. doi:10.1111/j.1755-5949.2010.00160.x [PubMed 20553304]
  227. Refer to manufacturer's labeling.
  228. Reinblatt SP, Riddle MA. Selective serotonin reuptake inhibitors-induced apathy: A pediatric case series. J Child Adolesc Psychopharmacol. 2006;6(1/2):227-233. [PubMed 16553543]
  229. Reisman Y. Sexual consequences of post-SSRI syndrome. Sex Med Rev. 2017;5(4):429-433. doi:10.1016/j.sxmr.2017.05.002 [PubMed 28642048]
  230. Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol. 2013;4:45. doi:10.3389/fphar.2013.00045 [PubMed 23596418]
  231. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167(2):188-194. doi:10.1001/archinte.167.2.188 [PubMed 17242321]
  232. Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. Bone. 2012;51(3):606-613. doi:10.1016/j.bone.2012.05.018 [PubMed 22659406]
  233. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426 [PubMed 14999113]
  234. Rogal SS, Hansen L, Patel A, et al. AASLD practice guidance: palliative care and symptom-based management in decompensated cirrhosis. Hepatology. 2022;76(3):819-853. doi:10.1002/hep.32378 [PubMed 35103995]
  235. Roy-Byrne PP, Craske M. Panic disorder in adults: Treatment overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 4, 2023.
  236. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol. 2016;34(6):611-635. doi:10.1200/JCO.2015.64.3809 [PubMed 26644543]
  237. Safarinejad MR, Hosseini SY. Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. Int J Impot Res. 2006;18(2):164-169. doi:10.1038/sj.ijir.3901384 [PubMed 16107866]
  238. Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol. 2006;16(1-2):159-169. doi:10.1089/cap.2006.16.159 [PubMed 16553536]
  239. Samuel NG, Seifert CF. Risk of bleeding in patients on full-dose enoxaparin with venous thromboembolism and selective serotonin reuptake inhibitors. Ann Pharmacother. 2017;51(3):226-231. doi:10.1177/1060028016677309 [PubMed 27834194]
  240. Sathianathen NJ, Hwang EC, Mian R, et al. Selective serotonin re-uptake inhibitors for premature ejaculation in adult men. Cochrane Database Syst Rev. 2021;3(3):CD012799. doi:10.1002/14651858.CD012799.pub2 [PubMed 33745183]
  241. Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry. 2006;67(suppl 4):27-30. [PubMed 16683860]
  242. Schirman S, Kronenberg S, Apter A, et al. Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study. J Neural Transm (Vienna). 2010;117(1):139-145. doi:10.1007/s00702-009-0330-x [PubMed 19851705]
  243. Schneider LS, Frangakis C, Drye LT, et al. Heterogeneity of treatment response to citalopram for patients with Alzheimer's disease with aggression or agitation: The CitAD randomized clinical trial. Am J Psychiatry. 2016;173(5):465-472. doi:10.1176/appi.ajp.2015.15050648 [PubMed 26771737]
  244. Schoretsanitis G, Augustin M, Saßmannshausen H, Franz C, Gründer G, Paulzen M. Antidepressants in breast milk; comparative analysis of excretion ratios. Arch Womens Ment Health. 2019;22(3):383-390. doi:10.1007/s00737-018-0905-3 [PubMed 30116895]
  245. Schoretsanitis G, Spigset O, Stingl JC, Deligiannidis KM, Paulzen M, Westin AA. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. Expert Opin Drug Metab Toxicol. 2020;16(5):431-440. doi:10.1080/17425255.2020.1750598 [PubMed 32238008]
  246. Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol. 2003;18(5):279-284. [PubMed 12920388]
  247. Shakoor M, Ayub S, Ahad A, Ayub Z. Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor. Am J Case Rep. 2014;15:562-564. doi:10.12659/AJCR.892264 [PubMed 25540831]
  248. Shams T, Firwana B, Habib F, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med. 2014;29(1):204-213. doi:10.1007/s11606-013-2535-9 [PubMed 23888328]
  249. Sharp SC, Hellings JA. Efficacy and safety of selective serotonin reuptake inhibitors in the treatment of depression in children and adolescents: Practitioner review. Clin Drug Investig. 2006;26(5):247-255. [PubMed 17163258]
  250. Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. Prim Care Companion J Clin Psychiatry. 2001;3(4):168-174. [PubMed 15014601]
  251. Shin D, Oh YH, Eom CS, Park SM. Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. J Neurol. 2014;261(4):686-695. doi:10.1007/s00415-014-7251-9 [PubMed 24477492]
  252. Shindel AW, Althof SE, Carrier S, et al. Disorders of ejaculation: an AUA/SMSNA guideline. J Urol. 2022;207(3):504-512. doi:10.1097/JU.0000000000002392 [PubMed 34961344]
  253. Siroosbakht S, Rezakhaniha S, Rezakhaniha B. Which of available selective serotonin reuptake inhibitors (SSRIs) is more effective in treatment of premature ejaculation? A randomized clinical trial. Int Braz J Urol. 2019;45(6):1209-1215. doi:10.1590/S1677-5538.IBJU.2019.0121 [PubMed 31808410]
  254. Sobieraj DM, Baker WL, Martinez BK, et al. Comparative effective review: Adverse effects of pharmacologic treatments of major depression in older adults. AHRQ Publication No. 19-EHC011-EF. March 2019; Number 2015.
  255. Spigset O, Hägg S, Stegmayr B, Dahlqvist R. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol. 2000;56(9-10):699-703. doi:10.1007/s002280000205 [PubMed 11214779]
  256. Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. Breastfeed Med. 2015;10(6):290-299. [PubMed 26204124]
  257. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51(3):215-235. doi:10.1016/s0165-0327(98)00221-3 [PubMed 10333979]
  258. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2003;64(11):1322-1327. [PubMed 14658946]
  259. Stein MB, Garcia KG, Pollack MH, et al. American Psychiatric Association practice guideline for the treatment of patients with panic disorder. https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines. Published January 2009. Accessed March 2023.
  260. Stein MB, Taylor CT. Social anxiety disorder in adults: Treatment overview. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 2, 2024.
  261. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42(9):1290-1297. doi:10.1345/aph.1L066 [PubMed 18628446]
  262. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. doi: 10.1210/jc.2015-2236. [PubMed 26444994]
  263. Su N, Wen C, Guo S, Yu Y, Wang C. The efficacy and tolerability of selective serotonin reuptake inhibitors for motor recovery in non-depressed patients after acute stroke: a meta-analysis. Front Neurol. 2021;12:749322. doi:10.3389/fneur.2021.749322 [PubMed 34744985]
  264. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587 [PubMed 18759711]
  265. Sylvester C, Menke M, Gopalan P. Selective serotonin reuptake inhibitors and fertility: considerations for couples trying to conceive. Harv Rev Psychiatry. 2019;27(2):108-118. doi:10.1097/HRP.0000000000000204 [PubMed 30676405]
  266. Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344-353. doi:10.4088/jcp.07m03780 [PubMed 19254516]
  267. Tahir N. Serotonin syndrome as a consequence of drug-resistant infections: An interaction between linezolid and citalopram. J Am Med Dir Assoc. 2004;5(2):111-113. [PubMed 14984623]
  268. Tampi RR, Balderas M, Carter KV, et al. Citalopram, QTc prolongation, and torsades de pointes. Psychosomatics. 2015;56(1):36-43. doi:10.1016/j.psym.2014.09.002 [PubMed 25619672]
  269. Tarchi L, Merola GP, Baccaredda-Boy O, et al. Selective serotonin reuptake inhibitors, post-treatment sexual dysfunction and persistent genital arousal disorder: a systematic review. Pharmacoepidemiol Drug Saf. 2023;32(10):1053-1067. doi:10.1002/pds.5653 [PubMed 37294623]
  270. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol. 2009;104(6):1475-1482. doi:10.1038/ajg.2009.128 [PubMed 19491861]
  271. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006a;43(2):180-187. doi:10.1086/504809 [PubMed 16779744]
  272. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry. 2006b;63(11):1217-1223. doi:10.1001/archpsyc.63.11.1217 [PubMed 17088502]
  273. Thomsen PH. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacol. 1997;7(3):157-166. [PubMed 9466233]
  274. Thomsen PH, Ebbesen C, Persson C. Long-term experience with citalopram in the treatment of adolescent OCD. J Am Acad Child Adolesc Psychiatry. 2001;40(8):895-902. [PubMed 11501688]
  275. Țieranu E, Donoiu I, Istrătoaie O, et al. Q-T interval prolongation in patients with liver cirrhosis. Curr Health Sci J. 2018;44(3):274-279. doi:10.12865/CHSJ.44.03.11 [PubMed 30647948]
  276. Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients [published correction appears in Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e57]. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152 [PubMed 23716032]
  277. Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients [published correction appears in Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):981]. Circ Cardiovasc Qual Outcomes. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651 [PubMed 24803473]
  278. Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. Circulation. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905 [PubMed 32929996]
  279. Tomlin AM, Reith DM, Woods DJ, et al. A pharmacoepidemiology database system for monitoring risk due to the use of medicines by New Zealand primary care patients. Drug Saf. 2017;40(12):1259-1277. doi:10.1007/s40264-017-0579-1 [PubMed 28766108]
  280. Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010;121(6):404-414. doi:10.1111/j.1600-0447.2009.01514.x [PubMed 19958306]
  281. Tseng WP, Tsai JH, Wu MT, Huang CT, Liu HW. Citalopram-induced serotonin syndrome: a case report. Kaohsiung J Med Sci. 2005;21(7):326-328. doi:10.1016/S1607-551X(09)70129-9 [PubMed 16089311]
  282. Tucker P, Potter-Kimball R, Wyatt DB, et al. Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Psychopharmacol Bull. 2003;37(3):135-149. [PubMed 14608246]
  283. Uguz F. Better tolerance of citalopram in a breastfed infant who could not tolerate sertraline and paroxetine. Breastfeed Med. 2018;13(1):89-90. doi:10.1089/bfm.2017.0168 [PubMed 29185803]
  284. US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of major depressive disorder. https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf. Updated February 2022. Accessed June 15, 2022.
  285. van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol. 2005;61(4):303-307. doi:10.1007/s00228-005-0921-x [PubMed 15906018]
  286. Varia I, Rauscher F. Treatment of generalized anxiety disorder with citalopram. Int Clin Psychopharmacol. 2002;17(3):103-107. [PubMed 11981350]
  287. Varigonda AL, Jakubovski E, Bloch MH. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2016;55(10):851-859.e2. doi:10.1016/j.jaac.2016.07.768 [PubMed 27663940]
  288. Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int. 2008;82(2):92-101. doi:10.1007/s00223-007-9099-9 [PubMed 18219438]
  289. von Knorring AL, Olsson GI, Thomsen PH, et al. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol. 2006;26(3):311-315. [PubMed 16702897]
  290. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T. The effect of citalopram in panic disorder. Br J Psychiatry. 1997;170:549-553. [PubMed 9330022]
  291. Wadhwa R, Kumar M, Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: A review of clinical studies and plausible mechanisms. Osteoporos Sarcopenia. 2017;3(2):75-81. doi:10.1016/j.afos.2017.05.002 [PubMed 30775508]
  292. Wagner KD. Pharmacotherapy for major depression in children and adolescents. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(5):819-826. [PubMed 15908090]
  293. Wagner KD, Robb AS, Findling RL, et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psych. 2004;161(6):1079-1083. [PubMed 15169696]
  294. Waldinger MD. Psychiatric disorders and sexual dysfunction. Handb Clin Neurol. 2015;130:469-489. doi:10.1016/B978-0-444-63247-0.00027-4 [PubMed 26003261]
  295. Waller M. Safer citalopram use in primary care: can staff education and prescribing prompts improve adherence to national guidance? A closed loop clinical audit, service evaluation and quality improvement study. J Family Med Prim Care. 2022;11(11):7085-7088. doi:10.4103/jfmpc.jfmpc_772_22 [PubMed 36993121]
  296. Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2020;59(10):1107-1124. doi:10.1016/j.jaac.2020.05.005 [PubMed 32439401]
  297. Wang CY, Fu SH, Wang CL, Chen PJ, Wu FL, Hsiao FY. Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study. Osteoporos Int. 2016;27(1):57-63. doi:10.1007/s00198-015-3213-z [PubMed 26126579]
  298. Warden SJ, Fuchs RK. Do selective serotonin reuptake inhibitors (SSRIs) cause fractures?. Curr Osteoporos Rep. 2016;14(5):211-218. doi:10.1007/s11914-016-0322-3 [PubMed 27495351]
  299. Warner, CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. Am Fam Physician. 2006;74:449-456. [PubMed 16913164]
  300. Weintraub D, Drye LT, Porsteinsson AP, et al. Time to response to citalopram treatment for agitation in Alzheimer disease. Am J Geriatr Psychiatry. 2015;23(11):1127-1133.
  301. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004;161(6):1066-1078. doi: 10.1176/appi.ajp.161.6.1066. [PubMed 15169695]
  302. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int. 2011;108(41):687-693. doi:10.3238/arztebl.2011.0687 [PubMed 22114630]
  303. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 1998;18(5):390-398. [PubMed 9790157]
  304. Williams AJ, Lai Z, Knight S, Kamali M, Assari S, McInnis MG. Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder. J Clin Psychiatry. 2018;79(3):17m11765. doi:10.4088/JCP.17m11765 [PubMed 29873955]
  305. Yager J, Devlin MJ, Halmi KA, et al; American Psychiatric Association. Guideline watch (August 2012): practice guideline for the treatment of patients with eating disorders, 3rd edition. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/eatingdisorders-watch.pdf. Published August 2012. Accessed June 21, 2021.
  306. Zisook S, Trivedi MH, Warden D, et al. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. J Affect Disord. 2009;117(1-2):63-73. doi:10.1016/j.jad.2009.01.002 [PubMed 19217668]
Topic 12972 Version 718.0